

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/70, 38/00, 39/00, 39/395, C12N 5/08, G01N 33/53, 33/564, 33/558</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/23082</b> <b>(43) International Publication Date:</b> 27 April 2000 (27.04.00)
<b>(21) International Application Number:</b> PCT/US99/24443 <b>(22) International Filing Date:</b> 19 October 1999 (19.10.99) <b>(30) Priority Data:</b> 60/104,816 19 October 1998 (19.10.98) US <b>(71) Applicant (for all designated States except US):</b> YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot (IL). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> COHEN, Irun, R. [US/IL]; Hankin Street 11, 76354 Rehovot (IL). ROTTER, Varda [IL/IL]; Mivtsah Kadesh 2, 75221 Rishon Lezion (IL). EREZ-ALON, Neta [IL/IL]; Lea Street 18, 69412 Tel Aviv (IL). HERKEL, Johannes [DE/DE]; Gottfried Kinkel Strasse 3, D-65187 Wiesbaden (DE). <b>(74) Agents:</b> BROWDY, Roger, L. et al.; Browdy and Neimark, P.L.L.C., 624 Ninth Street, N.W., Suite 300, Washington, DC 20001 (US).		<b>(81) Designated States:</b> CA, IL, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY DOWN-REGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS  <b>(57) Abstract</b>  Systemic lupus erythematosus (SLE) can be prevented or treated by down-regulating the autoimmune response to the C-terminal DNA-binding domain of the p53 protein (p53) by an active principle selected from the group consisting of: (i) a peptide of, or comprising, the C-terminal DNA-binding domain of the p53 protein; (ii) a monoclonal antibody (mAb) specific for said domain of p53 (Ab1), and fragments thereof; (iii) an mAb specific for Ab1 (hereinafter Ab2), and fragments thereof; (iv) a peptide based on a complementarity determining region (CDR) of the heavy or light chain of said Ab1 or Ab2; (v) a DNA molecule coding for (i) or (iv) or for the variable region of said Ab1 and Ab2 of (ii) and (iii); and (vi) T cells specific for (i) to (iv), fragments thereof, T cell receptor (TCR) thereof and peptides comprising the variable region of said TCR. SLE can also be diagnosed by assaying for antibodies (Ab1) against the C-terminal DNA-binding domain of p53 or antibodies (Ab2) specific to the Ab1 antibodies.		

555

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CC	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY DOWN-REGULATING  
THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS

FIELD OF THE INVENTION

5           The present invention is directed to a method for  
preventing or treating systemic lupus erythematosus (SLE) by  
down-regulating the autoimmune response to the major  
autoantigens that maintain the autoimmune reaction. It is  
also directed to diagnostic methods and kits for SLE, to  
10   pharmaceutical compositions for use in such treatment and  
diagnosis, and to novel peptides.

BACKGROUND OF THE INVENTION

          The rejection of transplanted cells and tissues of  
allogeneic origin proves that the immune system is capable of  
15   destroying its targets. However, in some cases, an  
individual's immune system destroys itself, resulting in an  
autoimmune disease such as diabetes mellitus, multiple  
sclerosis, rheumatoid arthritis, systemic lupus  
erythematosus, etc.

20           Antibodies to DNA are characteristic of many  
autoimmune diseases, notably systemic lupus erythematosus  
(SLE) and particularly lupus nephritis. However, there is at  
present no generally accepted explanation for the prevalence  
of anti-DNA antibodies in autoimmune disorders. Immunity to  
25   DNA appears to be driven by an antigen (Radic et al, 1994),  
but self-DNA is unlikely to be the driving antigen because  
mammalian DNA usually does not induce an anti-DNA immune  
response (Pisetsky, 1996).

          SLE is known to be associated with antibodies to  
30   various autoantigens, notably to DNA and to nuclear antigens.  
It is not clear, however, what drives and maintains the  
immune response to these antigens, and how such immunity  
might be involved in pathogenesis. It has been reported that  
certain common anti-DNA idiotypes can induce SLE in  
35   susceptible strains of mice (Mendlovic et al, 1988) and that

antibodies, anti-idiotypic to these common idiotypes, play a role in lupus development (Ward et al, 1997). However, the "natural" antigens of these idiotypic antibodies have not been defined.

5           It is the variable region of an antibody (antigen-binding site) which binds to an antigen. Therefore, the variable regions of antibodies have three-dimensional structures that are complementary to the structures of the antigenic determinants the antibodies recognize.

10           The binding site of the antibody complementary to the structure of the antigen is created by hypervariable regions of the light and heavy chains of the Fab portion of the antibody. These binding site structures are formed by the collective aggregate of the complementarity determining  
15 region (CDR) of the light and heavy chains of the immunoglobulin molecule. However, an antibody itself, when recognized by another antibody, can be considered to be an antigen. In the case where structures of the variable regions of the antibody are recognized, these structures are  
20 called idiotypes, and the antibodies that recognize the idiotypes of the antibody are called anti-idiotypic antibodies. The structure corresponding to the antigenic determinant of the antibody is called an idiotope.

          It has been reported that immunization with  
25 monoclonal antibodies can induce immune responses that extend beyond the specificity of the antibody, probably by anti-idiotypic connectivity based on idiotypic determinants in the variable regions of the immunizing monoclonal antibody. According to idiotypic antibody network terminology, Ab1 is  
30 the first antibody, the antibody binding to the antigen, and Ab2 is the anti-idiotypic antibody to Ab1. The variable region of Ab2 may mimic the conformation of the antigen because both the antigen and Ab2 can be bound by Ab1. Ab3 is the anti-idiotypic antibody to Ab2. Because of the chain of  
35 structural complementarity, Ab1 and Ab3 can have similar specificity for the original antigen.

Treatment of autoimmune disease has been shown to be possible by inducing immunological tolerance to the major autoantigens that maintain the autoimmune reaction, inducing an immune response which destroys T cells which attack the autoantigens, or inducing a TH1 → TH2 shift in the T cells reactive to the autoantigens. In experimental models of multiple sclerosis, for example, tolerance to myelin basic protein (MBP) and clinical improvement of disease could be achieved in a variety of ways:

1. T-cell vaccination with attenuated anti-MBP T cells (Ben-Nun et al, 1981);
2. Vaccination with peptides derived from the T cell receptor (TCR) of anti-MBP T cells (Vandenbark et al, 1989);
3. Vaccination with DNA encoding the TCR of anti-MBP T cells (Waisman et al, 1996);
4. Intravenous or intraperitoneal application of MBP or MBP-derived peptides (Gaur et al, 1992);
5. Oral tolerance induction by enteric administration of MBP or MBP-derived peptides (Higgins et al, 1988).

Similar techniques have been disclosed in U.S. patent 5,578,303 with respect to insulin dependent diabetes mellitus (IDDM) and the 65 kD heat shock protein, which is cross-reactive with the major autoantigen of IDDM. The entire contents of U.S. patent 5,578,303 are hereby incorporated herein by reference.

The p53 protein is a tumor-associated antigen which is the product of a tumor suppressor gene that functions to arrest the growth of mutated or aberrant cells (Baker et al, 1990). Functional p53 is believed to sense DNA damage (Lee et al, 1995) and subsequently induce DNA repair (Kastan et al, 1991), growth arrest (Kuerbitz et al, 1992), or apoptosis (Yonish-Rouach et al, 1991) of the aberrant cells. The sequence of murine p53, as reported in Shohat-Foord et al (1991), is set forth in SEQ ID NO:1. The DNA and amino acid

sequences of human p53, as reported in Harris et al (1986), are set forth in SEQ ID Nos:9 and 10.

The p53 protein has at least two DNA-binding sites:

(1) the core of the p53 protein, which interacts specifically with a DNA sequence in the promoters of p53-responsive genes (el-Deiry et al, 1992), and

(2) the C-terminus of the p53 protein, which can recognize features common to damaged DNA in general (Lee et al, 1995; Shohat-Foord et al, 1991).

The p53 protein is a transcription factor that binds specifically to a consensus site present in the regulatory sequences of p53-dependent genes (el-Deiry et al, 1992). Mutation of the p53 gene in the domain encoding binding to the specific DNA regulatory site causes a loss of tumor suppression. Therefore, it is not surprising that a significant proportion of natural human tumors bear mutated p53 (Hollstein et al, 1991).

Inactivation of the p53 tumor suppressor protein by mutation of the gene or by viral insertion, gene rearrangement, or other causes is a common event in human cancers. Point mutation or deletion of the p53 gene is the most common genetic aberration in human neoplasms. Approximately 70% of colon cancers, 30 to 50% of breast cancers, 50% of lung cancers, and almost 100% of small-cell carcinomas of the lung harbor p53 mutations (Hollstein et al, 1991). The p53 protein, both mutant and wild-type, can accumulate in the cytoplasm of cancer cells, and cancer patients have been found to produce antibody and T cell responses to p53. Normal cells express p53 to a much lower degree and, unlike tumor cells, normal cells show no accumulation of p53 in the cytoplasm. Thus, tumor cells and normal cells differ in both the amount and compartment of p53 expression. Although both mutated p53 and wild-type p53 have been used as immunogens for tumor immunotherapy, p53 is not very immunogenic, probably because it is a self-protein and, therefore, is immunologically tolerated.

In the laboratory of the present inventors, it has been observed that the immunization of BALB/c mice to an Ab1 anti-p53 antibody specific for a mutant domain of p53 could activate an idiotypic network leading to anti-mutant p53 immunity and resistance to a tumor (Ruiz et al, 1998; Erez-Alon et al, 1998). Mice were immunized with domain-specific anti-p53 monoclonal antibodies (Ab1): PAb-248 (Yewdell et al, 1986) directed to the N-terminus; PAb-246 (Yewdell et al, 1986; Cook et al, 1990) directed to the specific DNA-binding region; or PAb-240 directed to a mutant p53 that does not bind specific DNA. Immunized mice responded by making anti-idiotypic antibodies (Ab2) specific for Ab1 inducer. Ab1 PAb-246 induced Ab2 that, like p53 itself, could bind the specific DNA oligonucleotide sequence of the p53 responsive element. Mice immunized with Ab1 PAb-240 or PAb-246 spontaneously made Ab3 anti-p53 antibodies that reflected the specificity of their Ab1 inducers: Ab1 PAb-246 induced Ab3 specific for wild-type p53; PAb-240 induced Ab3 specific for mutant p53. Ab1 PAb-248 induced only Ab2. The spontaneously arising Ab3 were of T cell-dependent IgG isotypes. Peptides from the complementarity determining region of the Ab1 antibodies PAb-240 and PAb-246 could also induce Ab3 anti-p53. Finally, mice that produced Ab3 anti-p53 acquired resistance to tumor metastases. Therefore, an anti-idiotypic network built around certain domains of p53 seems to be programmed within the immune system, specific Ab2 antibodies can mimic the DNA binding domain of p53, and Ab3 network immunity to p53 can be associated with resistance to tumor cells.

30

#### SUMMARY OF THE INVENTION

It is an object of the present invention to treat or prevent autoimmune diseases involving an autoimmune reaction against DNA, including systemic lupus erythematosus (SLE).

It is another object of the present invention to provide peptide, antibody and T cell products and compositions for use in the treatment or prevention of SLE.

It is a further object of the present invention to  
5 provide a method for diagnosis of SLE.

It is yet another object of the present invention to provide methods and kits for use in the diagnosis of SLE.

These and other objects of the present invention are attained based on the discovery that injection of BALB/c  
10 mice with a monoclonal antibody which binds the non-specific DNA binding site at the C-terminus of p53 induced SLE in the immunized mice. Furthermore, an anti-idiotypic network was induced by this monoclonal antibody in the SLE-susceptible BALB/c mice. It was, thus, surmised that anti-idiotypic  
15 antibodies, specific to the monoclonal antibodies which are specific to the C-terminal DNA-binding domain of p53, attack not only the anti-p53 monoclonal antibodies but also the DNA bound by this domain of p53, thereby inducing the symptoms of SLE. Therefore, development of SLE and of anti-DNA  
20 antibodies appears to occur as a consequence of an idiotypic immune response to the DNA binding protein p53.

Since the development of experimental SLE is now discovered to be driven by an immune response to the DNA-binding domain of the C-terminus of the p53 protein,  
25 abrogation of the immune reaction can be expected to result in prevention of SLE or, in SLE patients, clinical improvement of SLE disease.

The present invention thus relates to a method for preventing or treating systemic lupus erythematosus (SLE) in  
30 a human, comprising down-regulating the autoimmune response in the human to the C-terminal DNA-binding domain of the p53 protein (p53). Said down-regulating step comprises administering to the human, in a manner that suppresses the autoimmune response to the C-terminal DNA-binding domain of  
35 the p53 protein, an active principle selected from the group consisting of:



(i) a peptide of the C-terminal DNA-binding domain of the p53 protein of the sequence consisting of the residues 364-383 of the p53 protein (residues 364-383 of SEQ ID NO:1) or a peptide or polypeptide including said sequence;

5 (ii) a monoclonal antibody (mAb) specific for the C-terminal DNA-binding domain of the p53 protein raised against a peptide or polypeptide of (i) (hereinafter Ab1), and fragments thereof;

(iii) a mAb specific for Ab1 (hereinafter Ab2), and  
10 fragments thereof;

(iv) a peptide based on a complementarity determining region (CDR) of the heavy or light chain of said Ab1 or Ab2 of (ii) or (iii), respectively;

(v) a DNA molecule coding for (i) or (iv) or for  
15 the variable region of said Ab1 and Ab2 of (ii) and (iii); and

(vi) T cells specific for (i) to (iv), fragments thereof, T cell receptor (TCR) thereof and peptides comprising the variable region of said TCR.

20 In one aspect of the invention, the active principle is the T cell as defined in (vi) above. It is preferably a T cell product selected from the group consisting of:

(a) activated human T cells that manifest  
25 specificity for the C-terminal DNA-binding domain of the p53 protein, or to a monoclonal antibody specific for the C-terminal DNA-binding domain of the p53 protein (Ab1), or to a monoclonal antibody specific for Ab1 (Ab2);

(b) said human T cells of (a) which have been  
30 attenuated by gamma- or UV irradiation or by pressure treatment by means of hydrostatic pressure, treatment with chemical cross-linking agent and/or treatment with a cytoskeletal cross-linking agent;

(c) fragments, or surface proteins shed from, the T  
35 cells of (a) or (b); and

(d) a T cell receptor (TCR) of the T cells of (a) or a peptide comprising the variable region of said TCR.

In a preferred embodiment of this aspect of the invention, the human T cells are ones which manifest  
5 specificity for the C-terminal DNA-binding domain of the p53 protein. In another preferred embodiment, the T cells are attenuated by gamma- or UV irradiation. The T cells may be autologous T cells from the patient to be treated or semi-allogeneic T cells from a donor sharing at least one HLA  
10 class II molecule with said patient, e.g., one of the parents or a sibling.

Abrogation or down-regulation of the immune reaction which causes SLE can be attained by inducing appropriate immunological tolerance or appropriate  
15 suppression of immune response in manners which are already known per se with respect to the prevention and treatment of other autoimmune diseases in which the major autoantigen is known. Among the ways that this immune reaction can be abrogated are the following.

20 T cell vaccination using attenuated autoimmune T cells constitutes a preferred embodiment of the invention. It activates regulatory mechanisms without paying the price of acute disease. Anti-idiotypic T cells quell the autoimmune T cells and so prevent the clinical emergence of  
25 the disease or result in clinical improvement of the disease. With respect to SLE, the complicated immunological response which it is desired to disrupt includes the antibodies which are generated in the SLE patient against the C-terminal DNA-binding domain of the p53 protein (the Ab1 antibodies) and  
30 the Ab2 antibodies which are generated against the Ab1 antibodies. As the Ab1 antibodies mimic the DNA to which the C-terminal domain of p53 interacts, it is the Ab2 antibodies which are specific to the Ab1 antibodies and, thus, cross-reactive with the DNA, thereby initiating the autoimmune  
35 attack against DNA, causing SLE. Thus, interruption of this idiotypic network, at any point, will down-regulate the

autoimmune response which causes the autoimmune anti-DNA attack which results in SLE.

Accordingly, T cell vaccination can be accomplished with T cell lines specific for the C-terminal DNA-binding domain of the p53 domain, T cells which are specific for the Abl antibody, or T cells which are specific for the Ab2 antibody. The T cells may be taken directly from a patient who is to be treated (autologous T cells) or may be obtained from a donor who shares at least one HLA class II molecule with the patient (semi-allogeneic T cells), e.g., from one of the parents or a sibling. These specific cells can be activated either by incubating in the presence of the antigen or by incubating with a mitogen capable of inducing an immune response by the T cells, such as Concanavalin A or phytohemagglutinin. Such activated T cells are preferably attenuated, preferably by gamma- or UV irradiation, or by a means of attenuation which also has the salutary effect of increasing the immunogenicity of the T cells, such as by pressure treatment by means of hydrostatic pressure of sufficient pressure and time to cause augmented immunogenicity of the T cells without substantial loss of membrane protein therefrom. Alternatively, the pressure may be of sufficient magnitude and duration to cause the cell surface proteins to be shed from the cells. After low speed centrifugation to remove the cells, the fragments obtained after high speed centrifugation may be used as the vaccine, as well as the soluble proteins remaining in the supernatant after high-speed centrifugation. All of these techniques are described in detail in European patent publication 261,648 of the present applicants, the entire contents of which being hereby incorporated herein by reference.

The specific, activated T cells may also be attenuated by treatment with a chemical cross-linking agent, such as formaldehyde, glutaraldehyde or a photoactivatable psoralen cross-linking agent, such as 8-methoxypsoralen (see European patent publication 333,606 to the present

applicants, the entire contents of which being hereby incorporated herein by reference). Such T cells may also be treated with a cytoskeletal disrupting agent, such as cytochalsin or colchicine. Any one or more of the pressure-treatment, chemical cross-linking treatment and cytoskeletal disrupting agent treatment steps can be combined. In addition, the cells so treated may be lysed and only the fixed cell membranes recovered and used. All of these processes are described in detail in European patent publication 261,648, incorporated by reference hereinabove.

The variable region of the T cell receptor specific for the p53 C-terminal DNA-binding domain, specific to the Ab1 antibody, or specific to the Ab2 antibody, and preferably the VDJ region or the VJ region of such T cell receptor, may be isolated and, preferably, cloned for expression and used as the T cell vaccine preparation of the present invention in the manner discussed in Howell et al (1989) and Vandembark (1989) for the autoimmune encephalomyelitis T cell receptor.

Alternatively, any of the antigens which generate antibodies or T cells within the idiotypic network which leads to the disease-causing Ab2 antibodies may be administered in such a way as to down-regulate the immune response, such as by causing a TH1 → TH2 shift or inducing anergy or otherwise inducing tolerance for the administered peptide so as to prevent an active immune attack thereagainst. Thus, the C-terminal DNA-binding domain of p53, Ab1 or at least the antigen binding domain of Ab1, or the corresponding T cell against the C-terminal DNA-binding domain of p53 (Tc1) or at least the variable region of the TCR thereof, or Ab2 or at least the antigen binding domain of Ab2, or the corresponding T cell (Tc2) or at least the variable region of the TCR thereof, may be administered in such a way as to create tolerance or anergy or otherwise to suppress immune response and cause a TH1 → TH2 shift, thus stopping the self-destruction of DNA. The active principle should be administered in such a manner so as to induce

anergy, create tolerance or otherwise cause a TH1 → TH2 shift, rather than inducing a damaging immunogenic response. Thus, it should not be administered in Complete Freund's Adjuvant or other strongly immunogenic adjuvant. One way of administering the active principle such that it will induce tolerance is to administer it with a carrier that favors induction of tolerance to the antigen when the antigen-carrier conjugate is administered. Such carriers are known as tolerogenic carriers. Examples of known tolerogenic carriers are polymers of D-amino acids, polyethylene glycol, polymers of sugar molecules, self-IgG molecules, self-spleen cells, and fatty acid molecules. An antigen may also be administered in a monomeric highly-soluble form to induce tolerance. They may be administered intravenously or intraperitoneally as was described for MBP or MBP-derived peptides by Gaur et al (1992). Another known method of inducing tolerance to an antigen is to administer it orally, even without any carrier specifically chosen for its tolerogenic characteristics, as was described, for example, for MBP or MBP-derived peptides by Higgins et al (1988).

A preferred method of administering such active principle is in conjunction with a metabolizable lipid emulsion, such as INTRALIPID or LIPOFUNDIN, which promotes a TH1 → TH2 cytokine shift. The use of such emulsions is described in detail in WO 97/02016, the entire contents of which being hereby incorporated herein by reference. Additionally, the efficacy of the treatment in accordance with the present invention can be detected and monitored by measuring for a TH1 → TH2 T cell response shift in the manner described in detail in WO 97/02052, the entire contents of which being hereby incorporated herein by reference.

In another aspect of the invention, the active principle is a peptide of the C-terminal DNA-binding domain of the p53 protein of the sequence consisting of the residues 364-383 of the p53 protein or a peptide or polypeptide including said sequence. In one embodiment, the peptide is

the peptide consisting of the residues 364-383 of the p53 protein (residues 364-383 of SEQ ID NO:1). In another embodiment, the polypeptide is the p53 protein.

In further aspects of the invention, the active principle is a monoclonal antibody selected from an Abl mAb specific for a polypeptide including the C-terminal DNA-binding domain of the p53 protein and an Ab2 mAb specific for a said Abl mAb.

A preferred Abl antibody in accordance with the present invention is the monoclonal antibody known as PAb-421 (Arai et al, 1986). This is an antibody against the C-terminal DNA-binding domain of murine p53 and was the antibody used in the tests of the present invention which proved induction of SLE in BALB/c mice, which tests are described in detail hereinbelow. The sequences of the variable heavy ( $V_H$ ) and variable light ( $V_L$ ) chains of the anti-p53 PAb-421 have been elucidated (see WO 98/56416) and as shown in Fig. 9 herein. The sequence for the heavy chain is SEQ ID NO:2 and that for the light chain is SEQ ID NO:3. The CDRs are underlined in Fig. 9. Of course, other monoclonal antibodies can be raised against the C-terminal DNA-binding domain of p53 and used in the methods of the present invention in a manner similar to that described herein for PAb-421. The  $V_H$  and  $V_L$  sequences of any such other antibodies can readily be determined by techniques known in the art, as well as the sequences of the complementarity determining regions (CDRs). Any such monoclonal antibody can be tested for its operability in the present invention by testing to determine if it binds to the C-terminal DNA-binding domain of p53 or to peptides derived from the C-terminal DNA-binding domain of p53. If it does, it falls within the definition of an Abl antibody in accordance with the present invention, i.e., an antibody which recognizes the C-terminal DNA-binding domain of p53.

Similarly, Ab2 monoclonal antibodies can readily be raised using the Abl antibody, or the antigen binding site

thereof, as an immunogen in the same manner as disclosed herein for the production of Abl monoclonal antibody.

Preferred Ab2 monoclonal antibodies prepared according to the present invention are those designated herein as IDI-1 and

5 IDI-2. The sequences of the  $V_H$  and  $V_L$  chains of IDI-1 and IDI-2 have been elucidated according to the present invention and are given in Fig. 9 and in SEQ ID NOs:4-7, respectively.

The CDRs are underlined in Fig. 9. Of course, other monoclonal antibodies can be raised against the antigen

10 binding site of an Abl antibody and used in the methods of the present invention in a manner similar to that described herein for IDI-1 and IDI-2. The  $V_H$  and  $V_L$  sequences of any such other antibodies can readily be determined by techniques known in the art, as well as the sequences of the CDRs. Any  
15 such monoclonal antibody can be tested for its operability in the present invention by testing to determine if it binds to an Abl antibody and to DNA. If it does, it falls within the definition of an Ab2 antibody in accordance with the present invention.

20 In still another aspect of the invention, the active principle is a peptide based on a CDR of the heavy or light chain of an Abl mAb raised against a polypeptide, including the C-terminal DNA-binding domain of the p53 protein, such as the anti-p53 mAb PAb-421. Based on the  
25 sequences of the heavy and light chains of PAb-421 described in PCT Publication WO 98/56416 and shown herein in Fig. 9, and in which the CDRs are underlined, the peptides of Fig. 10, herein designated PAb-421 H1 (residues 20-39 of SEQ ID NO:2), PAb-421 H2 (residues 48-67 of SEQ ID NO:2), PAb-421 H3  
30 (residues 93-111 of SEQ ID NO:2), PAb-421 L1 (residues 22-41 of SEQ ID NO:3), PAb-421 L2 (residues 49-67 of SEQ ID NO:3), and PAb-421 L3 (residues 89-108 of SEQ ID NO:3), have been synthesized. From these peptides, PAb-421 L3 has been described in WO 98/56416 and the others are novel.

35 In still a further aspect of the invention, the active principle is a peptide based on a CDR of the heavy or

light chain of an Ab2 mAb specific for an Ab1 mAb. The sequences of the heavy and light chains of the preferred anti-PAb-421 Ab2 mAb IDI-1 and IDI-2 are depicted in Fig. 9, in which the CDRs are underlined. Based on these sequences, the following novel peptides herein designated IDI-1 H1 (residues 22-41 of SEQ ID NO:4), IDI-1 H2 (residues 51-70 of SEQ ID NO:4), IDI-1 H3 (residues 97-115 of SEQ ID NO:4), IDI-1 L1 (residues 25-44 of SEQ ID NO:5), IDI-1 L2 (residues 52-70 of SEQ ID NO:5), and IDI-1 L3 (residues 92-110 of SEQ ID NO:5), IDI-2 H1 (residues 19-38 of SEQ ID NO:6), IDI-2 H2 (residues 49-67 of SEQ ID NO:6), IDI-2 H3 (residues 96-115 of SEQ ID NO:6), IDI-2 L1 (residues 11-29 of SEQ ID NO:7), IDI-2 L2 (residues 37-55 of SEQ ID NO:7), and IDI-2 L3 (residues 77-95 of SEQ ID NO:7), have been synthesized. These peptides and peptides obtained by extension or conservative amino acid substitution, and chemical derivatives of the foregoing, are encompassed by the present invention.

A "chemical derivative" of a peptide of the present invention, as defined herein, contains additional chemical moieties not normally a part of the peptide. Covalent modifications of the peptides are included within the scope of the invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Such derivatives include, but are not limited to, esters, N-acyl derivatives, and the like. Many such chemical derivatives and methods of making them are well known in the art.

Also included in the scope of the invention are salts, both organic and inorganic, of the CDR-based peptides.

The down-regulation of the immune response can be obtained not only by vaccinating attenuated T cells, but also by vaccinating with the TCR or peptides derived from the T cell receptor of any such T cells. Similarly, oligonucleotides may be obtained corresponding to the



rearranged T cell receptor genes of any of the cloned T cells which can be used for vaccination as described above. These oligonucleotides, encoding the TCR or parts thereof, may be cloned into suitable vectors and inoculated into patients so as to produce the desired peptides *in vivo*, such as is described in Waisman et al (1996), the entire contents of which being hereby incorporated herein by reference.

In still another aspect of the invention, the active principle is a DNA molecule encoding the peptide or polypeptide of the active principle and said DNA is administered in a manner in which said DNA is caused to express said active principle *in vivo*.

Another aspect of the present invention is in the area of diagnosis of SLE. If a patient shows the presence of Ab1 antibodies against the C-terminal DNA-binding domain of p53 or Ab2 antibodies against the Ab1 antibodies, there is reason to believe that the patient either has SLE or that an outbreak of the symptoms of SLE are imminent. Accordingly, such antibodies serve as a diagnostic marker for the presence or incipience of SLE. For example, it is important to monitor SLE patients who are in remission to obtain an early indication that reemergence of SLE symptoms may be imminent. This can be accomplished with the diagnostic techniques described herein.

Thus, the present invention relates to a method for diagnosing the presence or incipience of systemic lupus erythematosus (SLE) in a patient comprising testing said patient for the presence of antibodies (Ab1) against the C-terminal DNA-binding domain of the p53 protein or antibodies (Ab2) against the Ab1 antibodies, whereby a result indicating the positive presence of either said Ab1 or Ab2 antibodies indicates a high probability of the presence or incipience of SLE.

In another embodiment, the method for diagnosing for the presence or incipience of systemic lupus erythematosus (SLE) in a patient comprises testing said

patient for the presence of antibodies or T cells which immunoreact with the C-terminal DNA-binding domain of the p53 protein, or for antibodies or T cells which immunoreact with antibodies or T cells which are specific to the C-terminal DNA-binding domain of p53, whereby a result indicating the positive presence of such antibodies or T cells indicates a high probability of the presence or incipience of SLE.

One can assay for the presence of such diagnostic markers in the blood or urine being assayed by conventional techniques. For the *in vitro* serological tests, serum of a patient is contacted with Ab2 antibody to test for the presence of Ab1 antibody or contacted with Ab1 antibody to test for the presence of Ab2 antibody. Ab3 antibody raised against the Ab2 antibody may also be used in a serological test for the presence of Ab2 antibody. If the serum contains the antibodies being assayed for, an immunological reaction will occur, which may be detected and assayed by means of standard techniques, such as ELISA, agglutination, etc.

Any well-known immunoassay technique can be used to detect the presence of Ab1 or Ab2 antibodies or the corresponding T cells. It should be understood that once one of ordinary skill in the art becomes aware of the fact that the presence of Ab1 or Ab2 antibodies in the serum of a person, determined, for example, by means of an assay of antibodies thereagainst, is a positive indication of incipient or existing SLE, such artisans would be well aware of the types of immunoassay technique which can be used to determine whether such antibodies are present. Besides radioimmunoassay (solid or liquid phase), any conventional immunoassay technique can be used, such as enzyme-linked immunosorbent assay (ELISA), heterogeneous immunoassay (both competitive and non-competitive) using labels other than enzymes and radioisotopes, homogeneous immunoassays based on fluorescence quenching and enzyme channeling, immune precipitation (including radial immune diffusion) and agglutination assays based on visual semi-quantitative

detection or quantitative turbidimetric detection. The assay may use any conventional solid phase or sandwich assay techniques. The present invention is intended to comprehend all known means of immunodetection and labeling, e.g., enzyme, fluorescent, chemiluminescent, bioluminescent or radioactive, as are well known in the art. Such techniques are known, for example, from Harlow et al, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1988), Current Protocols in Immunology, eds. Coligan et al, Wiley & Sons, Inc. (1992-1996), and many other sources well known to those of ordinary skill in the art.

Similarly, kits may be prepared for carrying out any of the various assays used for accomplishing the present invention, such as kits comprising: (i) a peptide consisting of, or including, the C-terminal DNA-binding domain of the p53 protein, or an Ab1 mAb raised against said peptide or an Ab2 mAb specific for said Ab1 mAb; and (ii) a tagged antibody capable of recognizing the non-variable region of a human antibody. Each such kit would include all of the materials necessary to conduct a single assay or a fixed number of assays. For example, such a kit for determining the presence of Ab1 antibodies may contain solid-phase immobilized Ab2 antibodies and a tagged antibody capable of recognizing the non-variable region of the Ab1 antibody to be detected, such as tagged anti-human Fab. A kit for determining the presence of Ab2 antibodies may contain solid-phase immobilized Ab1 or Ab3 antibody which reacts or cross-reacts with Ab2, and a tagged antibody capable of recognizing the non-variable region of the Ab2 antibody to be detected, such as tagged anti-human Fab. The kit should also contain reagent capable of precipitating immune complexes of Ab1 or Ab2 and anti-Ab1 or Ab2 antibodies and may contain directions for using the kit and containers to hold the materials of the kit. Any conventional tag or label may be used, such as a radioisotope, an enzyme, a chromophore or a fluorophore. A typical radioisotope is iodine-125 or sulfur-35. Typical

enzymes for the purpose include horseradish peroxidase,  $\alpha$ -galactosidase and alkaline phosphatase.

Diagnostic compositions according to the present invention are prepared by combining Ab1 or Ab2 antibodies  
5 with suitable adjuvants and auxiliary components.

Another manner of conducting a diagnostic test is to inject Ab1 or Ab2 antibodies subcutaneously into a patient and to look for the occurrence of a detectable skin reaction. In the *in vivo* skin test, the skin reaction at the site of  
10 the injection is measured after a sufficient time period, for example, 24 to 72 hours after administration. Swelling and/or redness is due to a delayed hypersensitivity-like reaction.

The present invention further includes the novel  
15 monoclonal antibodies IDI-1 and IDI-2 and pharmaceutical and diagnostic peptides and compositions usable in the methods of the present invention.

Similarly, isolated T cells corresponding to Ab1 and Ab2, i.e., Tc1 and Tc2, are novel and part of the present  
20 invention, as are peptides made from the TCR's thereof. Such substances, as well as pharmaceutical compositions to be administered for down-regulating the immune response which causes SLE are also part of the present invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 Figure 1 is a graph showing induction of Ab2 antibodies by immunization to Ab1 anti-p53 antibodies. BALB/c mice (white bars) and C57BL/6 mice (black bars) were immunized with Ab1 PAb-246, PAb-248 or PAb-421, as indicated, and their Ab2 response to the (Fab)<sub>2</sub> fragments of the Ab1  
30 antibodies were detected. BALB/c mice made anti-idiotypic Ab2 antibodies with restricted specificity to their Ab1 inducers ( $P < 0.001$ ). C57BL/6 mice, in response to Ab1 PAb-246 or PAb-421, made Ab2 anti-idiotypes that were cross-reactive with both these Ab1 ( $P < 0.001$ ). In response to Ab1

Figure 2 is a graph showing cross-reactivity of C57BL/6 mouse Ab2 to PAb-246 and PAb-421. The Ab2 cross-reactivity between PAb-246 and PAb-421 of immunized C57BL/6 mice could be absorbed out significantly ( $P < 0.002$ ) by preincubation with PAb-246 (striped bars) or PAb-421 (white bars). Preincubation with PAb-248 (black bars) did not absorb out the cross-reactivity. The mean percent inhibition (+SD) of the reactivity to PAb-246 or PAb-421 by preincubation is shown.

Figure 3 is a graph showing Ab2 antibodies to single-stranded calf thymus DNA. Sera of BALB/c and C57BL/6 mice immunized to Ab1 PAb-246, PAb-248 or PAb-421 were tested for Ab2 antibodies to single-stranded DNA from calf thymus. BALB/c mice made significant titers of Ab2 anti-DNA, when immunized to Ab1 PAb-246 ( $P < 0.002$  when compared to PAb-248 or normal serum) or to PAb-421 ( $P < 0.001$ ). C57BL/6 mice immunized with either Ab1, in contrast, did not make a significant anti-DNA response, when compared to normal sera.

Figures 4A and 4B are graphs showing the induction of Ab3 anti-p53 antibodies by immunization to Ab1 anti-p53 antibodies. Sera of BALB/c mice and C57BL/6 mice immunized to the indicated Ab1 anti-p53 antibodies or normal sera were examined for their Ab3 antibodies reactive with p53. Ab3 anti-p53 antibodies were detected with an IgG-specific secondary antibody (Fig. 4A) or with secondary antibodies specific for the IgG1, IgG2A, IgG2B or IgG3 isotopes (Fig. 4B). The specific induction of Ab3 by immunization with Ab1 PAb-246 or PAb-421 in both strains was statistically significant ( $P < 0.0001$ ) when compared to normal sera. PAb-248 did not significantly induce anti-p53 antibodies.

Figure 5 is a graph showing induction of Ab3 anti-p53 antibodies reacting with the peptide epitope of PAb-421. Sera of BALB/c and C57BL/6 mice immunized to Ab1 PAb-246, PAb-248 or PAb-421 and normal sera were tested for antibodies that bind to a p53-derived peptide (364-383 of SEQ ID NO:1), which is the antigenic epitope of PAb-421. Only BALB/c mice

immunized with PAb-421 made antibodies to the peptide epitope of PAb-421 ( $P < 0.0001$ ). In contrast, C57BL/6 mice made no detectable antibodies to this peptide.

Figure 6 is a graph showing spontaneous increase of anti-PAb-421 and anti-p53 antibodies in MRL/MpJ-Fas<sup>lpr</sup> mice. At the age of 9 and 19 weeks, sera of MRL/MpJ-Fas<sup>lpr</sup> mice that develop SLE disease spontaneously were tested for antibodies that bind to p53, to a p53-derived peptide, which is the antigenic epitope of PAb-421, or to different anti-p53 monoclonal antibodies (PAb-421, PAb-248, PAb-246, PAb-240). The MRL/MpJ-Fas<sup>lpr</sup> mice, spontaneously on their way to SLE disease, developed rising tiers of antibodies reactive with p53, the p53 peptide epitope of PAb-421 and PAb-421 ( $P < 0.0001$ ). In contrast, they did not develop significant reactivity to the other anti-p53 antibodies PAb-248, PAb-246 and PAb-240.

Figure 7 is a graph showing the reactivities of monoclonal antibodies IDI-1 and IDI-2, which were selected for idiotypic binding to PAb-421. Neither IDI-1 nor IDI-2 showed binding to mouse monoclonal antibodies other than PAb-421 (Control mAb). The binding to single-stranded or double-stranded calf thymus DNA was assessed by ELISA after the DNA had been gamma-irradiated with the indicated dosages (0-10,000 rad).

Figure 8 is a graph showing the reactivity of human sera from SLE patients and healthy humans to antibodies to p53, to PAb-421 and to a control antibody, R73, that does not bind p53.

Figure 9 shows the sequences of the heavy chain and light chain variable regions of the monoclonal antibodies PAb-421 (SEQ ID NOs:2 and 3, respectively), IDI-1 (SEQ ID NOs:4 and 5, respectively) and IDI-2 (SEQ ID NOs:6 and 7, respectively). The CDRs are underlined.

Figure 10 shows the sequences of synthetic peptides comprising the CDRs of the heavy and light chains of

PAb-421, IDI-1 and IDI-2. The SEQ ID NOs for each are as follows:

	PAb-421	H1: residues 20-39 of SEQ ID NO:2
		H2: residues 48-67 of SEQ ID NO:2
5		H3: residues 93-111 of SEQ ID NO:2
	PAb-421	L1: residues 22-41 of SEQ ID NO:3
		L2: residues 49-67 of SEQ ID NO:3
		L3: residues 89-108 of SEQ ID NO:3
	IDI-1	H1: residues 22-41 of SEQ ID NO:4
10		H2: residues 51-70 of SEQ ID NO:4
		H3: residues 97-115 of SEQ ID NO:4
	IDI-1	L1: residues 25-44 of SEQ ID NO:5
		L2: residues 52-70 of SEQ ID NO:5
		L3: residues 92-110 of SEQ ID NO:5
15	IDI-2	H1: residues 19-38 of SEQ ID NO:6
		H2: residues 49-67 of SEQ ID NO:6
		H3: residues 96-115 of SEQ ID NO:6
	IDI-2	L1: residues 11-29 of SEQ ID NO:7
		L2: residues 37-55 of SEQ ID NO:7
20		L3: residues 77-95 of SEQ ID NO:7

#### DETAILED DESCRIPTION OF THE INVENTION

Treatment of autoimmune diseases driven by an immune response to p53, such as SLE, can be effected by down-regulating the autoimmune response to the C-terminus of the p53 protein and/or to antibodies in its idiotypic network. Abrogation of this immune reaction will result in prevention of SLE or clinical improvement of SLE.

The p53 molecule has two attributes of immunological interest: (1) because p53 binds DNA, immunity to p53 may lead to anti-DNA antibodies by an anti-id network; antibodies to a DNA-binding site of p53 can mimic DNA and, therefore, such anti-p53 antibodies might induce anti-DNA antibodies as anti-idiotypes; and (2) because p53 accumulates in transformed cells, immunity to p53 may have an anti-tumor effect.

The generation of antibodies to DNA has historically been difficult because the DNA molecule is poorly immunogenic. In particular, it would be desirable to obtain antibodies to specific DNA sequences, as such

5 antibodies can be used to detect the presence of such sequences for purposes of diagnosing whether an individual has a specific gene or promoter sequence. A specific antibody would have an advantage over currently used PCR techniques because antibody binding, unlike the polymerase

10 chain reaction, is easily quantifiable and needs no primers of enzymatic replication. In particular, sequence-specific anti-DNA antibodies can be used in diagnostics, for example, in detecting critical sequences in the breeding of animals and plants, in the identification of bacteria and other

15 parasites, in determining paternity and maternity, in forensic medicine, and perhaps even to generically identify damaged DNA. Specific anti-DNA antibodies also can be useful in the isolation of specific genes for DNA vaccination, gene cloning, and gene sequencing. Antibodies to specific

20 sequences of DNA might also be useful in activating or inhibiting particular genes for therapeutic purposes in plants, animals or humans. It has been shown that antibodies penetrate into living cells, and anti-DNA antibodies might be able to exert effects within living cells. However, DNA in

25 general, and certainly specific sequences of mammalian DNA, are not immunogenic.

Immunization of BALB/c mice to an Ab1 anti-p53 antibody specific for a mutant domain of p53 was found to activate an idiotypic network leading to anti-mutant p53

30 immunity and resistance to a tumor (Ruiz et al, 1998; Erez-Alon et al, 1998). By immunizing mice with Ab1 antibodies to three other domains of p53, it was found that Ab1 antibodies to either of the DNA-binding domains of p53 can induce anti-p53 anti-idiotypic antibodies in both BALB/c and C57BL/6

35 mice. Only the Ab1 to the C-terminal DNA-binding domain (PAb-421) induced SLE, and only in the BALB/c mice. The



specificities of the anti-idiotypic network induced by PAb-421 differed in the SLE-susceptible BALB/c and resistant C57BL/6 strains. MRL/MpJ-Fas<sup>lpr</sup> mice (Andrews et al, 1978), as they develop SLE disease spontaneously, make rising titers of anti-p53 antibodies and of Ab2 specific for PAb-421, but no Ab2 specific for other anti-p53 antibodies.

While the PAb-421 antibody against the C-terminal DNA-binding domain of p53 was raised against the C-terminal DNA-binding domain of murine p53, it should be understood that the C-terminus of the murine and the human p53 are both recognized by PAb-421. Indeed, it can be seen that there is an 11 amino acid residue sequence which is identical in the C-terminal DNA-binding domain of murine and human p53. See amino acids 369-379 of SEQ ID NO:1 and amino acids 372-382 of SEQ ID NO:10. This is why in Example 7 hereinbelow, for example, the murine antibodies were used to assess for human anti-p53.

While antibodies against murine p53 were used in the examples which follow, those of ordinary skill in the art will well understand that antibodies against equivalent regions of the human p53 protein, whose entire sequence is known and available (SEQ ID NO:10), can readily be raised without undue experimentation and used for the purposes of the present invention.

When using CDR peptides, either as direct therapeutics or as immunogens to raise antiidiotypic antibodies, the minimum number of amino acid residues to be used is 6-9. While 6 residues fit an antibody combining site, 9 are needed for T cell recognition as the MHC binding motifs for peptides need 9 amino acids. To make a synthetic peptide from the CDR region of the V<sub>H</sub> or V<sub>L</sub> sequences of an Ab1, Ab2, or Ab3 antibody, one should use 6-9 residues from within the CDR region. Longer peptides can also be used, including 1-10 residues from the natural sequence on either or both flanking sites of the core 6-9 residue region,

preferably to include all of the residues of the CDR region and at least 3 residues on either flank.

While the antibodies used for purposes of the present invention may be intact antibodies, preferably human  
5 monoclonal antibodies, it should be understood that it is the epitope binding site of the antibody which provides the desired function. Thus, besides the intact antibody, proteolytic fragments thereof such as the Fab or F(ab')<sub>2</sub> fragments can be used. Furthermore, the DNA encoding the  
10 variable region of the antibody can be inserted into other antibodies to produce chimeric antibodies (see, for example, U.S. Patent 4,816,567) or into T-cell receptors to produce T-cells with the same broad specificity (see Eshhar et al, 1990; Gross et al, 1989). Single chain antibodies can also  
15 be produced and used. Single chain antibodies can be single chain composite polypeptides having antigen binding capabilities and comprising a pair of amino acid sequences homologous or analogous to the variable regions of an immunoglobulin light and heavy chain (linked V<sub>H</sub>-V<sub>L</sub> or single  
20 chain F<sub>v</sub>). Both V<sub>H</sub> and V<sub>L</sub> may copy natural monoclonal antibody sequences or one or both of the chains may comprise a CDR-FR construct of the type described in U.S. Patent 5,091,513 (the entire contents of which are hereby incorporated herein by reference). The separate polypeptides  
25 analogous to the variable regions of the light and heavy chains are held together by a polypeptide linker. Methods of production of such single chain antibodies, particularly where the DNA encoding the polypeptide structures of the V<sub>H</sub> and V<sub>L</sub> chains are known, may be accomplished in accordance  
30 with the methods described, for example, in U.S. Patents 4,946,778, 5,091,513 and 5,096,815, the entire contents of each of which are hereby incorporated herein by reference.

When used in the present specification and claims, the recitation "a molecule including the antigen-binding  
35 portion of an antibody" is intended to include not only intact immunoglobulin molecules of any isotype and generated

by any animal cell line or microorganism, but also the reactive fraction thereof including, but not limited to, the Fab fragment, the Fab' fragment, the F(ab')<sub>2</sub> fragment, the variable portion of the heavy and/or light chains thereof, and chimeric or single-chain antibodies incorporating such reactive fraction, as well as any other type of molecule or cell in which such antibody reactive fraction has been physically inserted, such as a chimeric T-cell receptor or a T-cell having such a receptor, or molecules developed to deliver therapeutic or diagnostic labeling) moieties by means of a portion of the molecule containing such a reactive fraction.

In the pharmaceutical compositions of the present invention, the dosage of the active ingredient and the pharmaceutically acceptable excipient or carrier in the pharmaceutical composition can be readily determined by those of skill in the art.

#### EXAMPLE 1: Induction of SLE

##### Materials and Methods

##### 20 Mice and Antibodies

Female mice of the BALB/c or C57BL/6 strains were obtained from the animal breeding facilities at the Weizmann Institute of Science, Rehovot, Israel, and used at the age of 8-10 weeks. Mice were immunized with anti-p53 antibodies PAb-246, PAb-248, or PAb-421, which were purified from ascitic fluid by Protein A affinity chromatography (Sigma, Rehovot, Israel). Fifty micrograms of antibody emulsified in complete Freund's adjuvant were injected into the hind footpads. The mice were boosted twice at three-week intervals, subcutaneously in the flank with 20 micrograms of the antibodies in incomplete Freund's adjuvant. Sera were obtained ten days after the first boost. For detection of anti-histone antibodies, mice were bled again two weeks after a second boost. Female MRL/MpJ-Fas<sup>lpr</sup> mice were obtained from

Jackson, at the age of six weeks and bled twice, at the ages of 9 and 19 weeks.

#### Recombinant p53 and p53 Peptide Epitope of PAb-421

*E. coli* BL21 (DE3) cells were transformed with the T7 expression vector containing mouse p53 DNA (Shohat-Foord et al, 1991). P53 was purified as described (Wolkowicz et al, 1995). All peptides, including the p53 peptide epitope of PAb-421 (SYLKTKKGQSTSRHKKTVMVK) (residues 364-383 of SEQ ID NO:1) were prepared using an automated synthesizer (Abimed AMS 422; Langenfeld, Germany) according to the manufacturer. Peptide purity was tested by analytical reverse phase HPLC and mass spectroscopic analysis.

#### ELISA

ELISA assays were conducted in 96-well Maxisorp plates (Nunc, Roskilde, Denmark), which were coated with 10 mg test antigen per ml in PBS. After washing and blocking with 1% BSA in PBS for one hour at 37°C, diluted test sera (0.1 ml per well) was added for one hour at 37°C, followed by one hour incubation with goat anti-mouse IgG Fc specific, or IgG-isotype specific secondary antibodies conjugated to alkaline phosphatase, diluted 1:5000 (Jackson, Philadelphia, PA). A substrate solution containing 0.6 mg/ml of p-nitrophenylphosphate (Sigma, Rehovot, Israel) in diethanolamine-H<sub>2</sub>O, pH 9.8, was added, and the plates were read at 405 nm.

For anti-DNA ELISA, a secondary antibody conjugated to horseradish peroxidase, and as substrate 1 mg/ml ABTS in 0.2 M citric acid, 0.2 M Na<sub>2</sub>HPO<sub>4</sub>, and 3% H<sub>2</sub>O<sub>2</sub> (all from Sigma) was used. The test antigens used were (Fab)<sub>2</sub> fragments of Ab2 anti-PAb-421, which were prepared as described (Harlow et al, 1988), recombinant p53, the p53 peptide epitope of PAb-421, histones or, after pre-coating with methylated BSA, calf thymus DNA (all from Sigma). All antibody titers are shown as the O.D. produced by the test sera at a dilution of 1:100. Dots represent individual sera, bars represent the median of each group.

### Band Shift Assay

The band shift assay was performed as described (Wolkowicz et al, 1995) with the p53-responsive element oligonucleotide TCGAGAGGCATGTCTAGGCATGTCTC (SEQ ID NO:8) (el-  
5 Deiry et al, 1992). Briefly, 10-20 fmol of DNA was mixed with 4 microliters of test sera, two micrograms (2 microliters) of poly di dC, and a half reaction volume (8 microliters) of buffer (25 mM Tris-HCl, 100 mM KCl, 6.25 mM MgCl<sub>2</sub>, 0.5 mM EDTA, 1 mM DTT, and 10% glycerol), incubated for  
10 15 minutes on ice and for 15 minutes at room temperature. The reaction products were separated on 4% PAGE in a 0.4% TBE running buffer.

### Crithidia luciliae Assay

Slides with Crithidia were purchased from Immco  
15 (Buffalo, NY) and incubated with the test sera according to the manufacturer's protocol.

### Histology

Paraffin sections of tissue samples were either stained with hematoxillin and eosin, or immunostained with a  
20 peroxidase-labeled anti-mouse-IgG antibody (Jackson, Philadelphia, PA) and DAB (Sigma) according to the manufacturer's instructions.

### Detection of Proteinuria and Leukopenia

Proteinuria was detected with Albustix strips  
25 (Bayer, Slough, UK). Leukocytes were counted from heparinized blood following 10-fold dilution in 1% acetic acid.

### Statistics

The differences between experimental groups were  
30 tested for significance with the non-parametric Mann/Whitney U test.

### Induction of SLE-like Diseases by Ab1 Immunization

BALB/c and C57BL/6 mice were immunized with Ab1 PAb-246 or PAb-421 and were observed for the development of  
35 lupus. Mice of either strain immunized with Ab1 PAb-246 did not develop any sign of the disease. In contrast thereto,

BALB/c mice immunized with Ab1 PAb-421 were found to develop a lupus-like disease. Of the 80 BALB/c mice immunized with Ab1 PAb-421, about 95% exhibited proteinuria, ranging from 0.3 g/l to 3 g/l. Histologic examination of the kidneys showed protein deposition in tubuli and pathological changes in the glomeruli, marked by thickening of the glomerular basement membrane, "wire loop" formation, endothelial proliferation, neutrophilic exudation, deposition of hyaline material in the glomerular capillaries, and nuclear degeneration of cells. Seven out of ten BALB/c mice were found to be leukopenic ( $< 4000$  leukocytes per ml) and lymphopenic ( $< 1200$  lymphocyte per ml). About 30% of the mice immunized with PAb-421 developed significant titers of anti-histone antibodies, indicating that the immune response could spread to DNA-binding molecules other than p53.

In contrast to BALB/c mice, C57BL/6 mice immunized with Ab1 PAb-421 did not develop disease. Thus, it appears that, in a susceptible genetic background, an immune response to an Ab1 antibody specific for the C-terminal DNA-binding site of p53 can induce lupus.

#### Strain Differences in Ab2 Specificities

To learn whether both strains of mice responded to the Ab1 immunization by making Ab2 anti-idiotypic antibodies, the reactivity of their sera to the (Fab)<sub>2</sub> fragment of the Ab1 anti-p53 antibodies was determined. PAb-248 (Yewdell et al, 1986), which binds a p53 domain that does not appear to recognize DNA, was used as a control. As can be seen in Figure 1, the BALB/c mice manifested strict Ab2 specificity: those immunized to PAb-246 made specific antibodies to PAb-246; those immunized to PAb-248 made specific antibodies to PAb-248; and those immunized to PAb-421 made antibodies specific to PAb-421.

C57BL/6 mice, in contrast, made Ab2 antibodies that apparently cross-reacted to both PAb-246 and PAb-421 when immunized with PAb-426 or with PAb-421 (Figure 1). The Ab2 cross-reactivity of the C57BL/6 mice seemed to be limited to

PAb-246 and PAb-421. To confirm the Ab2 cross-reactivity between PAb-246 and PAb-421, tests were conducted to determine whether preincubation with either of the anti-p53 antibodies could absorb out the cross-reactivity. As shown in Figure 2, the Ab2 cross-reactivity between PAb-246 and PAb-421 of immunized C57BL/6 mice could be absorbed out significantly ( $P < 0.002$ ) by preincubation with PAb-246 (striped bars) or PAb-421 (white bars). Preincubation with PAb-246 (black bars) did not absorb out the cross-reactivity. The mean percent inhibition (+SD) of the reactivity to PAb-246 or PAb-421 by preincubation is shown.

#### Different Ab1 Antibodies Induce Different Ab2 anti-DNA Antibodies

Because Ab1 and PAb-421 interact with p53 domains that bind different types of DNA, it was possible that the induced Ab2 antibodies might, like p53, bind to different types of DNA. To analyze the specificity of the Ab2 anti-DNA antibodies, test sera for binding to DNA were examined in three different assay systems.

It had earlier been observed that Ab2 antisera of BALB/c mice that had been induced by Ab1 PAb-246 bound specifically to the oligonucleotide DNA sequence of the p53-responsive element in a band-shift assay. That observation was reconfirmed in a band-shift assay using BALB/c sera induced by immunization to PAb-246, PAb-248 or PAb-421. C57BL/6 sera induced by immunization to each of the Ab1 antibodies were also subjected to the band-shift assay. The results of this assay showed that BALB/c mice immunized to PAb-246 produced the band shift, i.e., anti-DNA Ab2 antibodies were detected. However, BALB/c mice immunized to PAb-421 or to PAb-248 did not make such anti-DNA antibodies. In contrast to the BALB/c mice, the Ab2 antibodies of C57BL/6 mice immunized to any of the Ab1 antibodies did not recognize the p53-responsive element.

Test sera were then examined for binding to DNA using the *Crithidia luciliae* assay, which detects antibodies to native, histone-free DNA exposed at the base of the *Crithidia* flagellum. Both BALB/c and C57BL/6 mice immunized to PAb-426 or PAb-248 were negative for anti-DNA antibodies in the *Crithidia* assay, as were C57BL/6 mice immunized to PAb-421. In contrast, BALB/c mice immunized to PAb-421 produced anti-DNA antibodies detectable by the *Crithidia* assay. The finding of positive reactivity in the *Crithidia* assay correlates with the clinical disease seen in the BALB/c mice. The *Crithidia luciliae* assay is used clinically for its diagnostic specificity for lupus in humans (Aarden et al, 1975). *Crithidia luciliae* is a protozoic organism and does not have a p53 gene. Thus, it is likely that its DNA does not contain p53-responsive elements, which explains why Ab1 PAb-246 did not induce anti-DNA which was detectable in the *Crithidia* assay.

Next, test sera were examined for binding to single stranded calf thymus DNA shown in Figure 3. High anti-DNA reactivity could be detected in BALB/c mice immunized with PAb-246 or with PAb-421. The majority of the C57BL/6 mice immunized to either anti-p53 Ab1, in contrast, showed no significant anti-DNA reactivity. Only a minority of C57BL/6 mice showed elevated anti-DNA reactivity, mostly those that had been immunized to Ab1 PAb-246.

Thus, Ab1 antibodies to the two different DNA-binding domains of p53 both induced Ab2 anti-DNA antibodies in BALB/c mice. Ab1 PAb-246 induced anti-DNA immunity that was specific for the p53-responsive element, and, in contrast, Ab1 PAb-421 induced anti-DNA antibodies to a type associated with lupus. The anti-DNA response of the C57BL/6 mice was relatively weak.

#### Generation of Ab3 anti-p53 Antibodies

To test whether immunization to Ab1 could induce Ab3, immunized mice were assayed for antibodies to p53. Both BALB/c mice and C57BL/6 mice were found to make anti-p53



antibodies in their idiotypic network responses to PAb-421 and PAb-246 (Figure 4A). However, Ab1 antibodies PAb-246 and PAb-421 induced a stronger Ab3 anti-p53 response in the BALB/c strain than they did in the C57BL/6 strain.

- 5 Immunization to Ab1 PAb-248 was less efficient in inducing Ab3 anti-p53 antibodies in either of the strains.

Figure 4B shows that the sera contained a mixture of Ab3 p53-reactive antibodies of different IgG isotypes including IgG2b. Since the Ab1 antibodies used for  
10 immunization were either of the IgG1 (PAb-246, PAb-248) or IgG2a isotypes (PAb-421), it appears likely that the anti-p53 antibodies detected were indeed the Ab3 products of the idiotypic network, rather than merely remnants of the immunizing Ab1 antibodies. The finding that Ab3 anti-p53  
15 were of T cell-dependent IgG isotypes implies the involvement of idiotype-specific T cells.

#### Strain Differences in Ab3 Specificities

Because the two mouse strains differed in their Ab1 response to PAb-421, it was conceivable that they also might  
20 differ in their Ab3 response to this Ab1 antibody. The specificity of the Ab3 response was analyzed by probing test sera for antibodies to the C-terminal peptide epitope of p53 that is recognized by the inducing PAb-421 (amino acids 364-383 of SEQ ID NO:1). Figure 5 shows that this p53 peptide  
25 was recognized by the Ab3 antibodies of the BALB/c mice.

In contrast, the C57BL/6 mice did not make antibodies to the C-terminal p53 peptide after Ab1 PAb-421 immunization, although they did make Ab3 anti-p53 antibodies of other specificities, as discussed above. Since the Ab2  
30 response of the C57BL/6 mice to PAb-421 was cross-reactive to PAb-246, as shown in Figures 1 and 2, it is conceivable that their Ab3 response was preferentially directed to the central p53 domain. Thus, the specificity of the Ab3 antibodies in the two strains differed: the Ab3 induced in BALB/c mice  
35 recognized the p53 epitope of the inducing Ab1 PAb-421, while

the Ab3 anti-p53 antibodies of C57BL/6 mice induced by Ab1 PAb-421 did not recognize the Ab1 epitope.

A comparison of the two mouse strains is summarized in Table 1.

5

Table 1  
Comparison of the Response to Ab1 PAb-421 Immunization  
of BALB/c and C57BL/6 Mice and of Spontaneous Immunity  
of MRL/MpJ-Fas<sup>lpr</sup> Mice

10

	BALB/c	C57BL/6	MRL/MpJ-Fas <sup>lpr</sup>
proteinuria (>0.3 g/l)	+	-	+
nephritis	+	-	+
leukopenia (< 4000/ml)	+	-	+
lymphopenia (< 1200 ml)	+	-	+
skin rashes	+	-	-
Ab2 Anti-PAb-421 antibodies	+	+	+
anti-native DNA antibodies (Crithidia)	+	-	+
anti-single-stranded DNA (calf thymus)	+	-	+
cross-reactive Ab2	-	+	not tested
Ab3 anti-p53 antibodies	+	+	+
Ab3 to C-terminus of p53	+	-	+
anti-histone antibodies	+	-	not tested

#### EXAMPLE 2: Idiotypic Recognition of PAb-421 in a Mouse

15

##### Strain that Develops SLE Spontaneously

To learn whether an idiotypic recognition of the C-terminus of p53 might also play a role in the spontaneous development of SLE, MRL/MpJ-Fas<sup>lpr</sup>, a strain that develops SLE spontaneously, was examined for the presence of antibodies to p53 and PAb-421. As can be seen in Figure 6, these mice,

20

spontaneously on their way to SLE, make rising titers of antibodies to p53, to the p53 peptide epitope of PAb-421, and to PAb-421, but not to other anti-p53 antibodies (PAb-248, PAb-246, PAb-240). Thus, it appears that the same idiotypic network that was associated with SLE induction in the BALB/c mice was also operative in the spontaneous disease development of the MRL/MpJ-Fas<sup>lpr</sup> mice.

As noted above, the immunization of BALB/c mice to two different Abl antibodies that each recognizes one of the two different DNA-binding domains of p53 resulted in idiotypic immune responses that included anti-DNA immunity. It is remarkable that the induced Ab2 anti-DNA in BALB/c mice apparently preserved the specificity of the DNA-binding domains of p53: immunization of Abl PAb-246 resulted in anti-DNA antibodies that bound specifically the p53-responsive element, and immunization to Abl PAb-421 resulted in non-specific DNA-binding detected in the *Crithidia* assay.

The immune response to Abl PAb-421 was associated with the development of murine lupus marked by a renal disorder (proteinuria and nephritis), hematologic disorders (leukopenia and lymphopenia), and an immunologic disorder (anti-DNA, anti-p53 and anti-histone antibodies). In contrast, the specific Ab2 anti-DNA response to the p53-responsive element of the BALB/c mice immunized to Abl PAb-246 did not lead to disease. Thus, the specificity of the anti-DNA immune response and its association with SLE disease is dictated by the specificity of the p53 DNA-binding domain.

A genetic influence on susceptibility was evident: BALB/c mice, but not C57BL/c mice, developed SLE by immunization to Abl PAb-421. Although both strains made Ab2 and Ab3 responses, the mice manifested major differences in their network specificities. The Ab2 response of the susceptible BALB/c mice was restricted to the Abl inducer, and was associated with reactivity to native DNA. The Ab2 response of the resistant C57BL/6 mice, in contrast, showed cross-reactivity to both PAb-421 and PAb-246, and was

dominated by anti-PAb-421 antibodies that did not bind to DNA. The different Ab2 responses of the two strains resulted in different Ab3 anti-p53 responses: the BALB/c mice made antibodies that, like the Abl inducer PAb-421, bound to the C-terminal p53 peptide. C57BL/6 mice, however, did not make such antibodies.

It was particularly interesting that the MRL/MpJ-Fas<sup>lpr</sup> mice, when they spontaneously developed SLE, made rising titers of antibodies with specificities that were associated with the development of SLE in the BALB/c strain: the MRL/MpJ-Fas<sup>lpr</sup> mice spontaneously made anti-p53 antibodies, including antibodies to the C-terminal p53 peptide epitope of PAb-421, and anti-idiotypic antibodies to PAb-421. Since these mice did not produce significant antibody titers specific for other monoclonal antibodies, including other anti-p53 antibodies, this finding strongly suggests that the same idiotypic network drives disease development also in spontaneous SLE.

The following examples relate to the isolation of monoclonal antibodies that mimic the carboxy terminal domain of p53 and the unexpected discovery that such monoclonal antibodies specifically bind to damaged DNA.

**EXAMPLE 3: Isolation of Monoclonal Antibodies that Mimic the Carboxy Terminal Domain of p53 and Bind Damaged DNA**

To generate such antibodies, BALB/c mice were immunized with PAb-421 and selected hybridomas producing anti-idiotypic antibodies that bound PAb-421 and could also bind DNA were isolated.

Two monoclonal antibodies, IDI-1 and IDI-2, could be isolated which had been selected for idiotypic binding to PAb-421 and their reactivities were determined. As shown in Fig. 7, both showed specific reactivity to PAb-421 and to DNA, single-stranded or double-stranded. No reactivity was found to mouse antibodies other than PAb-421, like R73. The

binding of IDI-1 and somewhat less of IDI-2 to single-stranded DNA was markedly enhanced after gamma-irradiation of the DNA, depending on the radiation dose absorbed by the DNA. This is remarkable, since p53 also shows preferential binding to DNA damaged by gamma-irradiation (Reed et al, 1995), as well as to single-stranded DNA ends (Selivanova et al, 1996). Thus, these two novel monoclonal antibodies of the present invention appear to mimic the DNA-binding specificity of p53. Thus, such antibodies could serve as models of the critical regulatory conformation of the carboxy-terminal domain of p53.

**EXAMPLE 4: The Monoclonal Antibodies IDI-1 and IDI-2 and Recognize a Similar DNA Motif**

Preliminary studies were done to define the oligonucleotide motifs recognized by IDI-1 and IDI-2 and to test whether p53 itself might bind the same oligonucleotide. Single-stranded homooligomers (20-mers) of dG, dA, dC and dT were used. In a band-shift assay, it was shown that IDI-1, IDI-2 and p53 bound to the dG oligomer better than they did the others. Thus, dG is an important ligand for the anti-DNA monoclonal antibodies and for p53 itself. This further supports the presumptions that IDI-1 and IDI-2 mimic the carboxy terminal conformation of p53. In fact, the binding of the antibody to oligo dG is evidence that the antibody actually mimics the C-terminal domain of p53.

**EXAMPLE 5: Oligo-dG Activates p53**

To test whether the oligo-dG ligand is a functional regulator of p53, we investigated whether oligo-dG might activate p53 to recognize the p53 responsive element. Preliminary results using a gel shift assay and labeled p53 responsive element indicate that the activation of p53 is 10-fold more sensitive to oligo-dG than to each of the other three oligomers of dA, dT or dC. Thus, a ligand found to bind to both p53 and to IDI-1 and IDI-2 seems to serve as a functional regulator of p53.

Accordingly, the present invention is also directed to Ab2 monoclonal antibodies, such as IDI-1 and IDI-2, raised against monoclonal antibodies specific to the C-terminal domain of p53, which Ab2 antibodies have the unique capability of binding to damaged DNA. Thus, such antibodies can be used not only to find damaged DNA, but also as a model to study the regulatory conformation of the carboxy terminal domain of p53.

The following examples are directed to methods of treatment of SLE in accordance with the present invention.

**EXAMPLE 6: Down-Regulation of SLE**

The above results indicated that a p53 immune network is associated with SLE. Thus, modulation of the p53 immune network should affect the course of SLE. A preliminary experiment was designed to see whether the spontaneous SLE development in MRL/MpJ-Fas<sup>lpr</sup> mice might be influenced by administering to these mice peptides involved in the p53 network: the CDR peptides of the light and the heavy chain of PAb-421 depicted in Fig. 10 (administered as a mixture), or peptide 364-383 (residues 364-383 of SEQ ID NO:1) of the carboxy terminal domain of p53. The mice were intraperitoneally injected with 100 mg of the p53 peptide epitope of PAb-421 in PBS, or with 100 mg of peptides derived from variable region of PAb-421 in PBS at weeks 12, 18, and 24 of age and followed for the development of SLE symptoms. As shown in Table 2, only 2 out of 5 mice (40%) treated with the p53 peptide epitope of PAb-421 (Table 2: 421-epitope) developed severe proteinuria at week 17 of age, compared to 6 out of 8 (75%) of the untreated control mice (Table 2: not treated) developing proteinuria. Treatment with the peptides derived from the variable region of PAb-421 protected all five mice from development of proteinuria (0%; Table 2: 421:CDR). At week 33 of age, 5 of 6 non-treated mice (83%, cf. Table 2) were dead, whereas none of the mice treated with either peptide had died (0% each; see Table 2).

Also carried out was T cell vaccination against immunity to PAb-421. MRL/MpJ mice were immunized intradermally with 30 mg of PAb-421 in complete Freund's adjuvant, followed by a boost in incomplete Freund's adjuvant. Cells derived from the draining lymph nodes, which were enriched for T cells reactive to PAb-421 and the p53 epitope peptide of PAb-421, were activated with 2 mg per ml Concanavalin A. Twelve week old MRL/MpJ-Fas<sup>lpr</sup> mice were then injected intraperitoneally with  $2 \times 10^7$  freshly activated and gamma-irradiated (2500 rad) cells per mouse. At 17 weeks of age, only 1 out of 8 treated mice (19%) developed severe proteinuria, while, in contrast, 6 out of 8 untreated control mice (75%) developed severe proteinuria. The results are shown in Table 2. 421-TCV vs. not treated.

Table 2  
Prevention of Spontaneous SLE in MRL/MpJ-Fas<sup>lpr</sup> Mice

	Not Treated	421-CDR	421-Epitope	421-TCV
heavy proteinuria, <sup>33</sup> g/l (+++) at week 17 of age	6/8 (75%)	0/5* (0%)	2/5 (33%)	1/8* (13%)
death by week 33 of age	5/6 (83%)	0/6* (0%)	0/6* (0%)	n.t

\* significantly different from the non-treated control group, as assessed by Fisher's exact probability test

#### EXAMPLE 7: Anti-p53 and anti-PAb-421 in Human SLE Patients

The finding of anti-p53 and anti-PAb-421 anti-idiotypic antibodies in the MRL/MpJ-Fas<sup>lpr</sup> mouse model suggested that human SLE patients might also produce such antibodies. Randomly collected sera of 25 SLE patients and of 14 healthy humans were surveyed for antibodies to p53, to PAb-421, and to another mouse antibody, R73, that does not

bind p53 (Figure 8). The SLE sera produced significantly higher titers of anti-p53 and anti-PAb421 antibodies than the healthy control sera. In contrast, there was no significant difference between SLE patients and healthy subjects in their antibody titers to R73. Thus, a random group of SLE patients manifested the same p53 associated antibodies observed in the MRL/MpJ-Fas<sup>lpr</sup> mice developing spontaneous SLE.

**EXAMPLE 8: T Cell Vaccination**

T cell lines specific for PAb-421, for peptides derived from the variable region of PAb-421, or for the p53 peptide epitope of PAb-421 or for IDI-1 or IDI-2 can be derived from peripheral blood lymphocytes (PBL) of SLE patients as described in Ota et al (1990). Briefly, PBL are separated from heparinized blood of SLE patients by Ficoll density gradient centrifuging. To obtain T cell lines, the PBL are repeatedly stimulated in tissue culture plates with 10 mg per ml of peptides derived from the variable regions of PAb-421, or with 10 mg per ml of the p53 peptide epitope of PAb-421 or IDI-1 or IDI-2 in the presence of a 5-20 fold greater concentration of gamma-irradiated (10,000 rad) autologous blood mononuclear cells, which are also derived by Ficoll density gradient centrifugation from heparinized blood. The stimulation can be performed in any suitable medium, such as RPMI 1640 medium, containing 10% autologous serum (or 10% pooled human AB serum), 1% HEPES buffer, 1% penicillin/ streptomycin, and 1% glutamine. Three days after stimulation, 5 U/ml of recombinant human interleukin-2 are added. The line T cells can be cloned by limiting dilution, as described in Zhang et al (1993), if desired.

For vaccination, freshly activated T cells are attenuated, e.g., by gamma-irradiation (8000 rad), and  $10^6$ - $10^8$  cells are injected subcutaneously in PBS as described in Zhang et al (1993), followed by several boosts with similar preparations.



**EXAMPLE 9: Vaccination with Peptides Derived from the T Cell  
Receptor (TCR)**

T cell clones specific for PAb-421, for peptides  
derived from the variable region of PAb-421, or for the p53  
5 peptide epitope of PAb-421 or IDI-1 or IDI-2 were obtained  
from SLE patients as described in Example 8. After DNA  
extraction and polymerase chain reaction-based amplification  
of the cloned rearranged TCR-genes, the oligonucleotide  
sequence of the product of the polymerase chain reaction is  
10 determined (Maniatis et al, 1982). From the oligonucleotide  
sequence, the amino acid sequence of the TCR can be deduced.

Synthetic peptides derived from the TCR of PAb-421-  
specific T cells, or from the TCR of T cells specific for the  
C-terminus of p53, or from the TCR of IDI-1 or IDI-2 specific  
15 T cells, are then used for vaccination as described  
(Vandenbark et al, 1996). Briefly, SLE patients are  
inoculated intradermally with 0.1-0.5 mg of the said peptide,  
followed by several boosts.

**EXAMPLE 10: Vaccination with Genes Encoding the TCR**

20 Oligonucleotides corresponding to the rearranged T  
cell receptor genes of cloned T cells, specific for peptides  
derived from the variable region of PAb-421, or specific for  
the p53 peptide epitope of PAb-421 or IDI-1 or IDI-2, are  
obtained as described in Example 9. These oligonucleotides  
25 encoding the TCR, or parts thereof, are then cloned into  
suitable vectors (Sato et al, 1996), and patients are  
inoculated with 0.01-1 mg of the DNA construct as described  
(Waisman et al, 1996).

**EXAMPLE 11: Anergy Induction by Intravenous or Subcutaneous  
Administration**

30 For anergy induction, 0.1-100 mg of PAb-421,  
peptides derived from variable region of PAb-421, p53, or of  
the p53 peptide epitope of PAb-421 or IDI-1 or IDI-2, are  
administered to SLE patients subcutaneously in adjuvant as  
35 described (Elias et al, 1994), or intravenously in PBS as  
described (Gaur et al, 1992).

**EXAMPLE 12: Anergy Induction by Enteric Administration (Oral Tolerance)**

Oral tolerance can be induced by daily enteric administration of 0.5-500 mg of p53, the p53 peptide epitope of PAb-421, PAb-421 or IDI-1 or IDI-2, or of peptides derived from the variable region of PAb-421 as described (Weiner et al, 1993).

To treat patients suffering from SLE, vaccine compositions can be prepared as follows:

10 A vaccine comprising activated T cell lines specific for PAb-421, for peptides derived from the variable regions of PAb-421, or for the p53 peptide epitope of PAb-421 or IDI-1 or IDI-2, together with a pharmaceutically acceptable carrier, can be administered through various routes known in the art, such as oral, intranasal, intravenous, subcutaneous, intramuscular, intraperitoneal, transdermal, or other known routes including the enteral route.

Alternatively, vaccines which are prepared from T cell clones specific for PAb-421, for peptides derived from the variable region of PAb-421, or for the p53 epitope of PAb-421 can be used together with a pharmaceutically acceptable carrier, can be administered through various routes known in the art, such as oral, intranasal, intravenous, subcutaneous, intramuscular, intraperitoneal, transdermal, or other known routes including the enteral route.

Oligonucleotides encoding the rearranged T cell receptor genes of cloned T cells specific for peptides derived from the variable region of PAb-421, or specific for the p53 peptide epitope of PAb-421, along with a pharmaceutically acceptable carrier, can be used to prepare vaccines to treat autoimmune diseases mediated by p53.

Compositions for intravenous or subcutaneous administration can be prepared from PAb-421, peptides derived from the variable region of PAb-421, p53, or of the p53

peptide epitope of PAb-421 and a pharmaceutically acceptable carrier. Alternatively, oral tolerance can be induced by daily enteric administration of p53, the p53 peptide epitope of PAb-421, PAb-421, or peptides derived from the variable  
5 region of PAb-421 and a pharmaceutically acceptable carrier for oral delivery.

The dosage of the peptide, oligonucleotide, etc. to be administered will depend on the type of compound used--an oligonucleotide, a peptide fragment, or a peptide, and upon  
10 the age, sex, weight, and condition of the recipient. The doses should not be so large as to cause adverse side effects such as unwanted cross-reactions, anaphylactic reaction, and the like.

Having now fully described this invention, it will  
15 be appreciated by those skilled in the art that the same can be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue  
20 experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or  
25 adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set  
30 forth as follows in the scope of the appended claims.

All references cited herein, including journal articles or abstracts, published or unpublished U.S. or foreign patent application, issued U.S. or foreign patents, or any other references, are entirely incorporated by  
35 reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the

entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known methods or conventional methods is not  
5 any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific  
embodiments will so fully reveal the general nature of the  
10 invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various application such specific embodiments, without undue experimentation, without departing from the general concept  
15 of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning an range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for  
20 the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

REFERENCES

- Aarden et al, "Immunology of DNA. III. *Crithidia luciliae*, a Simple Substrate for the Determination of anti-dsDNA with the Immunofluorescence Technique", Ann. NY Acad. Sci. 254:505-515 (1975)
- Andrews et al, Spontaneous Murine Lupus-like Syndromes, Clinical and Immunopathological Manifestations in Several Strains", J. Exp. Med. 148:1198-1215 (1978)
- Arai et al, "Immunologically Distinct p53 Molecules Generated by Alternative Splicing", Mol. Cell. Biol. 6:3232-9 (1986)
- Baker et al, Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53", Science 249:912-915 (1990)
- Ben-Nun et al, "Vaccination against Autoimmune Encephalomyelitis with T-lymphocyte Line Cells Reactive against Myelin Basic", Nature 292:60-61 (1981)
- Cohen, I.R., "The Cognitive Paradigm and the Immunological Homunculus", Immunol. Today 13:490-494 (1992)
- Cook et al, "Evidence for Allosteric Variants of Wild-type p53, a Tumour Suppressor Protein", Br. J. Cancer 61:548-552 (1990)
- Dong et al, "Initiation of Autoimmunity to the p53 Tumor Suppressor Protein by Complexes of p53 and SV40 Large T Antigen", J. Exp. Med. 179:1243-1252 (1994)
- el-Deiry et al, "Definition of a Consensus Binding Site for p53", Nat. Genet. 1:45-49 (1992)
- Elias et al, "Peptide Therapy for Diabetes in NOD Mice", Lancet 343:704-706 (1994)
- Erez-Alon et al, "Immunity to p53 Induced by an Idiotypic Network of anti-p53-antibodies: Generation of Sequence-specific anti-DNA Antibodies and Protection from Tumor Metastasis", Cancer Res. 58:5447-5452 (1998)
- Eshhar et al, "Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach", Br. J. Cancer Suppl. 10:27-29 (1990)

- Gaur et al, "Amelioration of Autoimmune Encephalomyelitis by Myelin Basic Protein Synthetic Peptide-induced Anergy", Science 258:1491-1494 (1992)
- Gross et al, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity", Proc. Natl. Acad. Sci. USA 86(24):10024-10028 (1989)
- Harlow et al, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (Cold Spring, 1988), p. 626
- Harris et al, "Molecular Basis for Heterogeneity of the Human p53 protein", Mol. Cell. Biol. 6:4650-4656 (1986)
- Higgins et al, "Suppression of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myelin Basic Protein and its Fragments", J. Immunol. 140:440-445
- Hollstein et al, "p53 Mutations in Human Cancers", Science 253:49-53 (1991)
- Howell et al, "Vaccination against Experimental Allergic Encephalomyelitis with T Cell Receptor Peptides", Science 246:688-670, 1989
- Kastan et al, "Participation of p53 Protein in the Cellular Response to DNA Damage", Cancer Res. 51:6304-6311 (1991)
- Kelley et al, "Interaction of Mutant lpr Gene with Background Strain Influences Renal Disease", Clin. Immunol. Immunopathol. 37:220-229 (1985)
- Kuerbitz et al, "Wild-type p53 Is a Cell Cycle Checkpoint Determinant Following Irradiation", Proc. Natl. Acad. Sci. USA 89:7491-7495 (1992)
- Lee et al, "p53 and Its 14 kDa C-terminal Domain Recognize Primary DNA Damage in the Form of Insertion/Deletion Mismatches", Cell 81:1013-1020 (1995)
- Linzer et al, "Characterization of a 54K Dalton Cellular SV40 Tumor Antigen Present in SV40-transformed Cells and Uninfected Embryonal Carcinoma Cells", Cell 17:43-52 (1979)
- Maniatis et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY, 1982)

- Mendlovic et al, "Induction of a Systemic Lupus Erythematosus-like Disease in Mice by a Common Human Anti-DNA Idiotype", Proc. Natl. Acad. Sci. USA 85:2260-2264 (1988)
- Moens et al, "In Vivo Expression of a single Viral DNA-binding Protein Generates Systemic Lupus Erythematosus-related Autoimmunity to Double-stranded DNA and Histones", Proc. Natl. Acad. Sci. USA 92:12393-12397 (1995)
- Ota et al, "T-cell Recognition of an Immunodominant Myelin Basic Protein Epitope in Multiple Sclerosis", Nature 346:183-187 (1990)
- Pisetsky, D.S., "The Immunologic Properties of DNA", J. Immunol. 156:421-423 (1996)
- Radic et al, "Genetic and Structural Evidence for Antigen Selection of Anti-DNA Antibodies", Annu. Rev. Immunol. 12:487-520 (1994)
- Reed et al, "The C-terminal Domain of p53 Recognizes DNA Damaged by Ionizing Radiation", Proc. Natl. Acad. Sci. USA 92:9455-9459 (1995)
- Ruiz et al, "Immunity to Mutant p53 and Tumor Rejection Induced by Idiotypic Immunization", Nat. Med. 4:710-712 (1998)
- Sato et al, "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization", Science 273:352-354 (1996)
- Selivanova et al, "The Single-stranded DNA End Binding Site of p53 Coincides with the C-terminal Regulatory Domain", Nucleic Acids Research 24:3560-3567 (1996)
- Shohat-Foord et al, "A DNA Binding Domain Is Contained in the C-terminus of Wild Type p53 Protein", Nucleic Acids Res. 19:5191-5198 (1991)
- Vandenbark et al, "Immunization with a Synthetic T-cell Receptor V-region Peptide Protects against Experimental Autoimmune Encephalomyelitis", Nature 341:541-544 (1989)
- Vandenbark et al, "Treatment of Multiple Sclerosis with T-cell Receptor Peptides: Results of a Double-blind Pilot Trial", Nat. Med. 2:1109-1115 (1996)

- Waisman et al, "Suppressive Vaccination with DNA Encoding a Variable Region Gene of the T-cell Receptor Prevents Autoimmune Encephalomyelitis and Activates Th2 Immunity", Nat. Med. 2:899-905 (1996)
- Ward et al, "Natural Antibodies that React with V-region Peptide Epitopes of DNA-binding Antibodies Are Made by Mice with Systemic Lupus Erythematosus as Disease Develops Immunology 92:354-361 (1997)
- Watanabe-Fukunaga et al, "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis", Nature 356:314-317 (1992)
- Weiner et al, "Double-blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis", Science 259:1321-1324 (1993)
- Wolkowicz et al, "The DNA Binding Activity of Wild Type p53 Is Modulated by Blocking its Various Antigenic Epitopes", Oncogene 10:1167-1174 (1995)
- Yewdell et al, "Monoclonal Antibody Analysis of p53 Expression in Normal and Transformed Cells", J. Virol. 59:444-452 (1986)
- Yonish-Rouach et al, Wild-type p63 Induces Apoptosis of Myeloid Leukaemic Cells that Is Inhibited by Interleukin-6", Nature 352:345-347 (1991)
- Zhang et al, "MHC-restricted Depletion of Human Myelin Basic Protein-reactive T Cells by T Cell Vaccination", Science 261:1451-1454 (1993)



WHAT IS CLAIMED IS:

1. The use of an active principle selected from the group consisting of:

(i) a peptide of the C-terminal DNA-binding domain of the p53 protein of the sequence consisting of the residues 364-383 of the p53 protein (residues 364-383 of SEQ ID NO:1) or a peptide or polypeptide including said sequence;

(ii) a monoclonal antibody (mAb) specific for the C-terminal DNA-binding domain of the p53 protein raised against a peptide or polypeptide of (i) (hereinafter Ab1), and fragments thereof;

(iii) a mAb specific for Ab1 (hereinafter Ab2), and fragments thereof;

(iv) a peptide based on a complementarity determining region (CDR) of the heavy or light chain of said Ab1 or Ab2 of (ii) or (iii), respectively;

(v) a DNA molecule coding for (i) or (iv) or for the variable region of said Ab1 and Ab2 of (ii) and (iii); and

(vi) T cells specific for (i) to (iv), fragments thereof, T cell receptor (TCR) thereof and peptides comprising the variable region of said TCR, for the preparation of a pharmaceutical composition for down-regulating the autoimmune response in the human to the C-terminal DNA-binding domain of the p53 protein (p53).

2. The use according to claim 1, wherein said pharmaceutical composition is for preventing or treating systemic lupus erythematosus (SLE).

3. The use in accordance with claim 1 or 2, wherein said active principle is a T cell product selected from the group consisting of:

(a) activated human T cells that manifest specificity for the C-terminal DNA-binding domain of the p53 protein, or to a monoclonal antibody specific for the C-

terminal DNA-binding domain of the p53 protein (Ab1), or to a monoclonal antibody specific for Ab1 (Ab2);

(b) said human T cells of (a) which have been attenuated by gamma- or UV irradiation or by pressure treatment by means of hydrostatic pressure, treatment with chemical cross-linking agent and/or treatment with a cytoskeletal cross-linking agent;

(c) fragments, or surface proteins shed from, the T cells of (a) or (b); and

(d) a T cell receptor (TCR) of the T cells of (a) or a peptide comprising the variable region of said TCR.

4. The use in accordance with claim 3, wherein said human T cells of (a) are ones which manifest specificity for the C-terminal DNA-binding domain of the p53 protein.

5. The use in accordance with claim 3 or 4, wherein said T cell product is said attenuated human T cells of claim 3(b).

6. The use in accordance with any one of claims 3 to 5, wherein said human T cells are autologous T cells from the patient to be treated or semi-allogeneic T cells from a donor sharing at least one HLA class II molecule with said patient.

7. The use according to claim 1 or 2, wherein said active principle is a peptide of claim 1(i).

8. The use in accordance with claim 7, wherein said active principle is the peptide of the C-terminal DNA-binding domain of the p53 protein of the sequence consisting of the residues 364-383 of the p53 protein (residues 364-383 of SEQ ID NO:1).

9. The use in accordance with claim 7, wherein said active principle is a polypeptide including the residues 364-383 of the p53 protein (residues 364-383 of SEQ ID NO:1).

10. The use in accordance with claim 9, wherein said polypeptide is the p53 protein.

11. The use in accordance with claim 1 or 2, wherein said active principle is an Abl mAb specific for a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

12. The use in accordance with claim 11, wherein said Abl mAb is the anti-p53 mAb PAb-421.

13. The use in accordance with claim 1 or 2, wherein said active principle is an Ab2 mAb specific to an Abl mAb raised against a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

14. The use in accordance with claim 13, wherein said Ab2 mAb is selected from the Ab2 anti-mAb PAb-421 IDI-1 and IDI-2 mAbs.

15. The use in accordance with claim 1 or 2, wherein said active principle is a peptide based on a CDR of the heavy or light chain of an Abl mAb raised against a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

16. The use in accordance with claim 15, wherein said peptide is based on a CDR of the heavy or light chain of the anti-p53 mAb PAb-421.

17. The use in accordance with claim 16, wherein said peptide is selected from the peptides herein designated PAb-421 H1 (residues 20-39 of SEQ ID NO:2), PAb-421 H2 (residues 48-67 of SEQ ID NO:2), PAb-421 H3 (residues 93-111 of SEQ ID NO:2), PAb-421 L1 (residues 22-41 of SEQ ID NO:3), PAb-421 L2 (residues 49-67 of SEQ ID NO:3), and PAb-421 L3 (residues 89-108 of SEQ ID NO:3).

18. The use in accordance with claim 1 or 2, wherein said active principle is a peptide based on a CDR of the heavy or light chain of an Ab2 mAb specific for an Abl mAb raised against a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

19. The use in accordance with claim 18, wherein said peptide is based on a CDR of the heavy or light chain of the anti-PAb-421 IDI-1 mAb.

20. The use in accordance with claim 19, wherein said peptide is selected from the peptides herein designated IDI-1 H1 (residues 22-41 of SEQ ID NO:4), IDI-1 H2 (residues 51-70 of SEQ ID NO:4), IDI-1 H3 (residues 97-115 of SEQ ID NO:4), IDI-1 L1 (residues 25-44 of SEQ ID NO:5), IDI-1 L2 (residues 52-70 of SEQ ID NO:5), and IDI-1 L3 (residues 92-110 of SEQ ID NO:5).

21. The use in accordance with claim 18, wherein said peptide is based on a CDR of the heavy or light chain of the anti-PAb-421 IDI-2 mAb.

22. The use in accordance with claim 21, wherein said peptide is selected from the peptides herein designated IDI-2 H1 (residues 19-38 of SEQ ID NO:6), IDI-2 H2 (residues 49-67 of SEQ ID NO:6), IDI-2 H3 (residues 96-115 of SEQ ID NO:6), IDI-2 L1 (residues 11-29 of SEQ ID NO:7), IDI-2 L2 (residues 37-55 of SEQ ID NO:7), and IDI-2 L3 (residues 77-95 of SEQ ID NO:7).

23. The use in accordance with claim 1 or 2, wherein said active principle is a DNA molecule encoding the peptide or polypeptide of the active principle, said DNA being formulated so as to be administered in a manner in which said DNA is caused to express said active principle *in vivo*.

24. A method for diagnosing the presence or incipience of systemic lupus erythematosus (SLE) in a patient, comprising testing said patient for the presence of antibodies (Ab1) against the C-terminal DNA-binding domain of the p53 protein or antibodies (Ab2) against the Abl antibodies, whereby a result indicating the positive presence of either said Ab1 or Ab2 antibodies indicates a high probability of the presence of incipience of SLE.

25. A method for diagnosing for the presence or incipience of systemic lupus erythematosus (SLE) in a patient, comprising testing said patient for the presence of antibodies or T cells which immunoreact with the C-terminal DNA-binding domain of the p53 protein (p53) or for antibodies or T cells which immunoreact with antibodies or T cells which are specific to the C-terminal DNA-binding domain of p53, whereby a result indicating the positive presence of such antibodies or T cells indicates a high probability of the presence or incipience of SLE.

26. A kit for diagnosing the presence or incipience of systemic lupus erythematosus (SLE), comprising:

(i) a peptide comprising the C-terminal DNA-binding domain of the p53 protein (p53) or an Ab1 monoclonal antibody raised against said C-terminal DNA-binding domain of p53, or an Ab2 monoclonal antibody specific for the variable region of said Ab1 monoclonal antibody; and

(ii) a tagged antibody capable of recognizing the non-variable region of a human antibody.

27. A pharmaceutical composition for preventing or treating systemic lupus erythematosus (SLE) comprising a pharmaceutically acceptable carrier and an active principle selected from the group consisting of:

(i) a peptide of the C-terminal DNA-binding domain of the p53 protein of the sequence consisting of the residues 364-383 of the p53 protein (residues 364-383 of SEQ ID NO:1) or a peptide or polypeptide including said sequence;

(ii) a monoclonal antibody (mAb) specific for the C-terminal DNA-binding domain of the p53 protein raised against a peptide or polypeptide of (i) (hereinafter Ab1), and fragments thereof;

(iii) a mAb specific for Ab1 (hereinafter Ab2), and fragments thereof;

(iv) a peptide based on a complementarity determining region (CDR) of the heavy or light chain of said Ab1 or Ab2 of (ii) or (iii), respectively;

(v) a DNA molecule coding for (i) or (iv) or for the variable region of said Ab1 and Ab2 of (ii) and (iii); and

(vi) T cells specific for (i) to (iv), fragments thereof, T cell receptor (TCR) thereof and peptides comprising the variable region of said TCR.

28. A pharmaceutical composition in accordance with claim 27, wherein said active principle is a T cell product selected from the group consisting of:

(a) activated human T cells that manifest specificity for the C-terminal DNA-binding domain of the p53 protein, or to a monoclonal antibody specific for the C-terminal DNA-binding domain of the p53 protein (Ab1), or to a monoclonal antibody specific for Ab1 (Ab2);

(b) said human T cells of (a) which have been attenuated by gamma- or UV irradiation or by pressure treatment by means of hydrostatic pressure, treatment with chemical cross-linking agent and/or treatment with a cytoskeletal cross-linking agent;

(c) fragments, or surface proteins shed from, the T cells of (a) or (b); and

(d) a T cell receptor (TCR) of the T cells of (a) or a peptide comprising the variable region of said TCR.

29. A pharmaceutical composition in accordance with claim 28, wherein said human T cells of (a) are ones which manifest specificity for the C-terminal DNA-binding domain of the p53 protein.

30. A pharmaceutical composition in accordance with claim 28 or 29, wherein said T cell product is said attenuated human T cells of claim 28(b).

31. A pharmaceutical composition in accordance with any one of claims 28 to 30, wherein said human T cells are

autologous T cells from the patient to be treated or semi-allogeneic T cells from a donor sharing at least one HLA class II molecule with said patient.

32. A pharmaceutical composition in accordance with claim 27, wherein said active principle is the peptide of the C-terminal DNA-binding domain of the p53 protein of the sequence consisting of the residues 364-383 of the p53 protein (residues 364-383 of SEQ ID NO:1).

33. A pharmaceutical composition in accordance with claim 27, wherein said active principle is a polypeptide including the residues 364-383 of the p53 protein (residues 364-383 of the p53 protein).

34. A pharmaceutical composition in accordance with claim 33, wherein said polypeptide is the p53 protein.

35. A pharmaceutical composition in accordance with claim 27, wherein said active principle is an Ab1 mAb specific for a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

36. A pharmaceutical composition in accordance with claim 35, wherein said Ab1 mAb is the anti-p53 mAb PAb-421.

37. A pharmaceutical composition in accordance with claim 35, wherein said active principle is an Ab2 mAb specific to an Ab1 mAb raised against a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

38. A pharmaceutical composition in accordance with claim 37, wherein said Ab2 mAb is selected from the Ab2 anti-mAb PAb-421 IDI-1 and IDI-2 mAbs.

39. A pharmaceutical composition in accordance with claim 27, wherein said active principle is a peptide based on a CDR of the heavy or light chain of an Ab1 mAb raised against a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

40. A pharmaceutical composition in accordance with claim 39, wherein said peptide is based on a CDR of the heavy or light chain of the anti-p53 mAb PAb-421.

41. A pharmaceutical composition in accordance with claim 40, wherein said peptide is selected from the peptides herein designated PAb-421 H1 (residues 20-39 of SEQ ID NO:2), PAb-421 H2 (residues 48-67 of SEQ ID NO:2), PAb-421 H3 (residues 93-111 of SEQ ID NO:2), PAb-421 L1 (residues 22-41 of SEQ ID NO:3), PAb-421 L2 (residues 49-67 of SEQ ID NO:3), and PAb-421 L3 (residues 89-108 of SEQ ID NO:3).

42. A pharmaceutical composition in accordance with claim 27, wherein said active principle is a peptide based on a CDR of the heavy or light chain of an Ab2 mAb specific for an Ab1 mAb raised against a polypeptide including the C-terminal DNA-binding domain of the p53 protein.

43. A pharmaceutical composition in accordance with claim 42, wherein said peptide is based on a CDR of the heavy or light chain of the anti-PAb-421 IDI-1 mAb.

44. A pharmaceutical composition in accordance with claim 43, wherein said peptide is selected from the peptides herein designated IDI-1 H1 (residues 22-41 of SEQ ID NO:4), IDI-1 H2 (residues 51-70 of SEQ ID NO:4), IDI-1 H3 (residues 97-115 of SEQ ID NO:4), IDI-1 L1 (residues 25-44 of SEQ ID NO:5), IDI-1 L2 (residues 52-70 of SEQ ID NO:5), and IDI-1 L3 (residues 92-110 of SEQ ID NO:5).

45. A pharmaceutical composition in accordance with claim 42, wherein said peptide is based on a CDR of the heavy or light chain of the anti-PAb-421 IDI-2 mAb.

46. A pharmaceutical composition in accordance with claim 45, wherein said peptide is selected from the peptides herein designated IDI-2 H1 (residues 19-38 of SEQ ID NO:6), IDI-2 H2 (residues 49-67 of SEQ ID NO:6), IDI-2 H3 (residues 96-115 of SEQ ID NO:6), IDI-2 L1 (residues 11-29 of SEQ ID



NO:7), IDI-2 L2 (residues 37-55 of SEQ ID NO:7), and IDI-2 L3 (residues 77-95 of SEQ ID NO:7).

47. A pharmaceutical composition in accordance with claim 27, wherein said active principle is a DNA molecule encoding the peptide or polypeptide of the active principle, said DNA being formulated so as to be administered in a manner in which said DNA is caused to express said active principle *in vivo*.

48. A kit for diagnosing the presence or incipience of systemic lupus erythematosus (SLE) in a patient, comprising a peptide consisting of, or including, the C-terminal DNA-binding domain of the p53 protein, or an Ab2 mAb specific for an Ab1 mAb raised against said peptide, for testing for the presence of antibodies (Ab1) against the C-terminal DNA-binding domain of the p53 protein in a body fluid of said patient.

49. A kit for diagnosing the presence or incipience of systemic lupus erythematosus (SLE) in a patient, comprising monoclonal antibodies (Ab1) against the C-terminal DNA-binding domain of the p53 protein, for testing for the presence of antibodies (Ab2) against the Ab1 antibodies, in a body fluid of said patient.

50. A kit in accordance with claim 48 or 49, comprising:

a peptide consisting of or including, the C-terminal DNA-binding domain of the p53 protein, or an Ab1 mAb raised against said peptide or an Ab2 mAb specific for said Ab1 mAb, and a tagged antibody capable of recognizing the non-variable region of a human antibody.

51. A method for preventing or treating systemic lupus erythematosus (SLE) in a human, comprising down-regulating the autoimmune response in the human to the C-terminal DNA-binding domain of the p53 protein (p53).

52. A method in accordance with claim 51 for treating SLE in a human patient suffering from SLE.

53. A method in accordance with claim 51 or 52, wherein said down-regulating step comprises administering to the human, in a manner which suppresses the autoimmune response to the C-terminal DNA-binding domain of p53, an active principle which is a molecule comprising a polypeptide selected from the group consisting of:

(a) a portion of p53 which includes the C-terminal DNA-binding domain thereof;

(b) the antigen binding domain of an antibody (Ab1) or T cell (Tc1) which manifests specificity against the C-terminal DNA-binding domain of p53;

(c) the antigen binding domain of an antibody (Ab2) which manifests specificity against Ab1 or the TCR of Tc1, or the TCR of a T cell (Tc2) which manifests specificity against the antigen binding domain of Ab1 or the TCR of Tc1; and

(d) a fraction of (a) or (c) which can be used as an immunogen to raise antibodies, the anti-idiotypic antibodies of which bind to DNA, or a fraction of (b) which can be used as an immunogen to raise antibodies which bind to DNA.

54. A method in accordance with claim 53, wherein said active principle is administered by administering DNA encoding the protein or polypeptide of the active principle in a manner in which said DNA is caused to express said active principle *in vivo*.

55. A method in accordance with claim 53, wherein said active principle is a portion of p53 which includes the C-terminal DNA-binding domain thereof.

56. A method in accordance with claim 53, wherein said active principle is the antigen binding domain of an antibody (Ab1) or T cell (Tc1) which manifests specificity against the C-terminal DNA-binding domain of p53.

57. A method in accordance with claim 56, wherein said antibody Ab1 is PAb-421.

58. A method in accordance with claim 56, wherein said active principle is the PAb-421 monoclonal antibody.

59. A method in accordance with claim 53, wherein said active principle is the antigen binding domain of an antibody (Ab2) which manifests specificity against Ab1 or the TCR of Tc1, or the TCR of a T cell (Tc2) which manifests specificity against the antigen binding domain of Ab1 or the TCR of Tc1.

60. A method in accordance with claim 59, wherein said active principle is the IDI-1 or IDI-2 monoclonal antibody.

61. A method in accordance with claim 53, wherein said active principle is a fraction of (a) or (c) which can be used as an immunogen to raise antibodies, the anti-idiotypic antibodies of which bind to DNA, or a fraction of (b) which can be used as an immunogen to raise antibodies which bind to DNA.

62. A method in accordance with claim 61, wherein said fraction is a peptide including the CDR of the heavy or light chain of antibody Ab1 or the CDR of the heavy or light chain of antibody Ab2.

63. A method in accordance with claim 62, wherein said peptide is one which includes a sequence selected from the group consisting of residues 26-35, 50-66 and 99-105 of SEQ ID NO:2, residues 24-39, 55-61 and 94-102 of SEQ ID NO:3, residues 28-37, 52-68 and 101-111 of SEQ ID NO:4, residues 27-42, 58-64 and 97-105 of SEQ ID NO:5, residues 26-35, 50-66 and 99-113 of SEQ ID NO:6, and residues 13-27, 43-49 and 82-90 of SEQ ID NO:7.

64. A method in accordance with claim 51 or 52, wherein said down-regulating step comprises administering to a human, in a manner that suppresses the autoimmune response to

the C-terminal DNA-binding domain of the p53 protein, an active principle selected from the group consisting of:

- (a) activated human T cells which manifest specificity for the C-terminal domain of p53, human T cells which manifest specificity for a monoclonal antibody specific to the C-terminal DNA-binding domain of the p53 protein (Ab1), or human T cells which manifest specificity for monoclonal antibodies which are specific for the Ab1 antibody (Ab2);
- (b) said human T cells of (a) which have been attenuated by gamma- or UV irradiation;
- (c) said human T cells of (a) which have been subjected to pressure treatment by means of hydrostatic pressure, treatment with chemical cross-linking agent and/or treatment with a cytoskeletal cross-linking agent;
- (d) fragments of, or surface proteins shed from, the T cells of (a), (b) or (c); and
- (e) a peptide comprising the variable region of the T cell receptor of the T cells of (a).

65. A method in accordance with claim 64, wherein said T cell product is said human T cells of (a).

66. A method in accordance with claim 64, wherein said T cell product is said attenuated T cells of (b) or said treated T cells of (c).

67. A method in accordance with claim 64, wherein said T cell product is said fragments or shed proteins of (d).

68. A method in accordance with claim 64, wherein said T cell product is said peptide (e).

69. A method in accordance with claim 64, wherein said human T cells are autologous T cells from the patient to be treated or semi-allogeneic T cells from a donor sharing at least one HLA class II molecule with said patient.

70. A method in accordance with claim 64, wherein said human T cells of (a) are ones which manifest specificity to the C-terminal domain of p53.

71. A method in accordance with claim 64, wherein said human T cells of (a) are ones which manifest specificity to said Ab1 antibodies.

72. A method in accordance with claim 64, wherein said human T cells of (a) are ones which manifest specificity to said Ab2 antibodies.

73. A method in accordance with claim 64, wherein said T cell product is administered in a manner which causes an immune response to be mounted against said T cell product.

74. A peptide comprising the complementarity determining region of the heavy or light chain of an antibody which manifests specificity against the C-terminal DNA-binding domain of p53, with the proviso that said peptide is not residues 89-108 of SEQ ID NO:3.

75. A peptide in accordance with claim 74 having a sequence selected from the group consisting of residues 20-39, 48-67 and 93-111 of SEQ ID NO:2 and residues 22-41 and 49-67 of SEQ ID NO:3.

76. A peptide comprising the complementarity determining region of the heavy or light chain of an antibody which manifests specificity against the antigen binding domain of an antibody which manifests specificity against the C-terminal DNA-binding domain of p53.

77. A peptide in accordance with claim 76 having a sequence selected from the group consisting of residues 22-41, 51-70 and 97-115 of SEQ ID NO:4, residues 25-44, 52-70 and 92-110 of SEQ ID NO:5, residues 19-38, 49-67 and 96-115 of SEQ ID NO:6, and residues 11-29, 37-55 and 77-95 of SEQ ID NO:7.

78. A peptide selected from the peptides herein designated:


PAb-421 H1 (residues 20-39 of SEQ ID NO:2)  
PAb-421 H2 (residues 48-67 of SEQ ID NO:2)  
PAb-421 H3 (residues 93-111 of SEQ ID NO:2)  
PAb-421 L1 (residues 22-41 of SEQ ID NO:3)

PAb-421 L2 (residues 49-67 of SEQ ID NO:3)  
IDI-1 H1 (residues 22-41 of SEQ ID NO:4)  
IDI-1 H2 (residues 51-70 of SEQ ID NO:4)  
IDI-1 H3 (residues 97-115 of SEQ ID NO:4)  
IDI-1 L1 (residues 25-44 of SEQ ID NO:5)  
IDI-1 L2 (residues 52-70 of SEQ ID NO:5)  
IDI-1 L3 (residues 92-110 of SEQ ID NO:5)  
IDI-2 H1 (residues 19-38 of SEQ ID NO:6)  
IDI-2 H2 (residues 49-67 of SEQ ID NO:6)  
IDI-2 H3 (residues 96-115 of SEQ ID NO:6)  
IDI-2 L1 (residues 11-29 of SEQ ID NO:7)  
IDI-2 L2 (residues 37-55 of SEQ ID NO:7)  
IDI-2 L3 (residues 77-95 of SEQ ID NO:7)

and peptides obtained by extension or conservative amino acid substitutions of the above peptides, and chemical derivatives of the foregoing.

1 / 8

FIG. 1



2 / 8

FIG. 2





FIG. 3





3 / 8

FIG. 4A




FIG. 5






FIG. 4B



5 / 8

FIG. 6



6 / 8

FIG. 7





FIG. 8



*FIG. 9*

PAb-421 heavy chain variable region:

QVKLQESGAELVRSGASVKLSCTASGFNIKDYMHVVKQRPEQGLEWIGWIDPE  
NGDTEYAPKFQGGKATMTADTSSNTAYLQLSSLASEDTAVYYCNFYGDALDYWG  
QGTTVTVSS

PAb-421 light chain variable region:

DIQLTQSPLTSLVTIGQPASISCKSSQSLDSDGKTYLNWLLQRPQGSPKRLIYLV  
SKLD SGVPDRFTGSGSGTDFTLKINRVEAEDLG VYYC WQGTHSPLTFGAGTKLK

IDI-1 heavy chain variable region:

IPQVQLQQSGAELVRPGASVKLSCKASGYIFTSYWINWVRQRPQGQGLEWIGNISP  
ADSSTNYNQKFKDKATLTVDKSSSTAYMQLSRPTFEDSAVYYCAREEVRRRRD  
MDFWGQGTSTVTSSAKTTPPC

IDI-1 light chain variable region:

RKLDIVITQDELSNPVTSGESVSISCRSRQSLLYKNGKTYLNWFLQRPQGSPQLLI  
YLMSIRASGVSDRFSGNGSGTDFTLEISRVAEDVG VYYC QQLVEYPYTFGGGT  
KLEIKRADAAPT

IDI-2 heavy chain variable region:

QVQLQQSGPELVKPGASMKISCKASGYSTGYTINWVKQSHGKNLEWIGLINPY  
NGGTCYNPKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCARRVWLRRDGE  
YYAMDYWGQGTSTVTSSAKTTPP

IDI-2 light chain variable region:

AVSLGQRATISQASESVSFAGTSLMHVYQQKPGQPPKLLIYRASKLESGVPAR  
FSGSGSESDFTLTIDPVEEDDAAMYCMQSMEDPYTFGGGTKLEIKRADAAPTV  
SIFPPS

*FIG. 10*

PAb-421 H1: L-S-C-T-A-S-G-F-N-I-K-D-Y-Y-M-H-W-V-K-Q-COOH

PAb-421 H2: I-G-W-I-D-P-E-N-G-D-T-E-Y-A-P-K-F-Q-G-K-COOH

PAb-421 H3: V-Y-Y-C-N-F-Y-G-D-A-L-D-Y-W-G-Q-G-T-T-COOH

PAb-421 L1: S-C-K-S-S-Q-S-L-L-D-S-D-G-K-T-Y-L-N-W-L-COOH

PAb-421 L2: P-K-R-L-I-Y-L-V-S-K-L-D-S-G-V-P-D-R-F-COOH

PAb-421 L3: G-V-Y-Y-C-W-Q-G-T-H-S-P-L-T-F-G-A-G-T-K-COOH

IDI-1 H1: L-S-C-K-A-S-G-Y-I-F-T-S-Y-W-I-N-W-V-R-Q-COOH

IDI-1 H2: G-N-I-S-P-A-D-S-S-T-N-Y-N-Q-K-F-K-D-K-A-COOH

IDI-1 H3: Y-C-A-R-E-E-V-R-R-R-R-D-M-D-F-W-G-Q-G-COOH

IDI-1 L1: S-C-R-S-R-Q-S-L-L-Y-K-N-G-K-T-Y-L-N-W-F-COOH

IDI-1 L2: P-Q-L-L-I-Y-L-M-S-I-R-A-S-G-V-S-D-R-F-COOH

IDI-1 L3: G-V-Y-Y-C-Q-Q-L-V-E-Y-P-Y-T-F-G-G-G-T-COOH

IDI-2 H1: K-I-S-C-K-A-S-G-Y-S-F-T-G-Y-T-I-N-W-V-K-COOH

IDI-2 H2: G-L-I-N-P-Y-N-G-G-T-C-Y-N-P-K-F-K-G-K-COOH

IDI-2 H3: C-A-R-R-V-W-L-R-R-D-G-F-Y-Y-A-M-D-Y-W-G-COOH

IDI-2 L1: S-C-Q-A-S-E-S-V-S-F-A-G-T-S-L-M-H-W-Y-COOH

IDI-2 L2: P-K-L-L-I-Y-R-A-S-K-L-E-S-G-V-P-A-R-F-COOH

IDI-2 L3: A-M-Y-Y-C-M-Q-S-M-E-D-P-Y-T-F-G-G-G-T-COOH

## SEQUENCE LISTING

<110> COHEN, Irun R.  
 ROTTER, Varda  
 HERKEL, Johannes  
 EREZ-ALON, Neta

<120> TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY  
 DOWNREGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS

<130> cohen35a

<140> not yet received

<141> 1999-10-19

<150> 60/104,816

<151> 1998-10-19

<160> 10

<170> PatentIn Ver. 2.0

<210> 1

<211> 390

<212> PRT

<213> Mus sp.

<400> 1

Met Thr Ala Met Glu Glu Ser Gln Ser Asp Ile Ser Leu Glu Leu Pro  
 1 5 10 15

Leu Ser Gln Glu Thr Phe Ser Gly Leu Trp Lys Leu Leu Pro Pro Glu  
 20 25 30

Asp Ile Leu Pro Ser Pro His Cys Met Asp Asp Leu Leu Leu Pro Gln  
 35 40 45

Asp Val Glu Glu Phe Phe Glu Gly Pro Ser Glu Ala Leu Arg Val Ser  
 50 55 60

Gly Ala Pro Ala Ala Gln Asp Pro Val Thr Glu Thr Pro Gly Pro Val  
 65 70 75 80

Ala Pro Ala Pro Ala Thr Pro Trp Pro Leu Ser Ser Phe Val Pro Ser  
 85 90 95

Gln Lys Thr Tyr Gln Gly Asn Tyr Gly Phe His Leu Gly Phe Leu Gln  
 100 105 110

Ser Gly Thr Ala Lys Ser Val Met Cys Thr Tyr Ser Pro Pro Leu Asn  
 115 120 125

Lys Leu Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln Leu Trp Val  
 130 135 140

Ser Ala Thr Pro Pro Ala Gly Ser Arg Val Arg Ala Met Ala Ile Tyr  
 145 150 155 160

Lys Lys Ser Gln His Met Thr Glu Val Val Arg Arg Cys Pro His His  
 165 170 175

Glu Arg Cys Ser Asp Gly Asp Gly Leu Ala Pro Pro Gln His Leu Ile  
 180 185 190

Arg Val Glu Gly Asn Leu Tyr Pro Glu Tyr Leu Glu Asp Arg Gln Thr  
 195 200 205

Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu Ala Gly Ser  
 210 215 220

Glu Tyr Thr Thr Ile His Tyr Lys Tyr Met Cys Asn Ser Ser Cys Met  
 225 230 235 240

Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr Leu Glu Asp  
 245 250 255

Ser Ser Gly Asn Leu Leu Gly Arg Asp Ser Phe Glu Val Arg Val Cys  
 260 265 270

Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn Phe Arg Lys  
 275 280 285

Lys Glu Val Leu Cys Pro Glu Leu Pro Pro Gly Ser Ala Lys Arg Ala  
 290 295 300

Leu Pro Thr Cys Thr Ser Ala Ser Pro Pro Gln Lys Lys Lys Pro Leu  
 305 310 315 320

Asp Gly Glu Tyr Phe Thr Leu Lys Ile Arg Gly Arg Lys Arg Phe Glu  
 325 330 335

Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala His Ala  
 340 345 350

Thr Glu Glu Ser Gly Asp Ser Arg Ala His Ser Ser Tyr Leu Lys Thr  
 355 360 365



Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Thr Met Val Lys Lys  
 370 375 380

Val Gly Pro Asp Ser Asp  
 385 390

<210> 2  
 <211> 116  
 <212> PRT  
 <213> Mus sp.

<220>  
 <221> BINDING  
 <222> (26)..(35)  
 <223> Complementary Determining Region

<220>  
 <221> BINDING  
 <222> (50)..(66)  
 <223> Complementary Determining Region

<220>  
 <221> BINDING  
 <222> (99)..(105)  
 <223> Complementary Determining Region

<400> 2  
 Gln Val Lys Leu Gln Glu Ser Gly Ala Glu Leu Val Arg Ser Gly Ala  
 1 5 10 15

Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Tyr  
 20 25 30

Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile  
 35 40 45

Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe  
 50 55 60

Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr  
 65 70 75 80

Leu Gln Leu Ser Ser Leu Ala Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Asn Phe Tyr Gly Asp Ala Leu Asp Tyr Trp Gly Gln Gly Thr Thr Val

100

105

110

Thr Val Ser Ser

115

&lt;210&gt; 3

&lt;211&gt; 110

&lt;212&gt; PRT

&lt;213&gt; Mus sp.

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (24)..(39)

&lt;223&gt; Complementary Determining Region

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (55)..(61)

&lt;223&gt; Complementary Determining Region

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (94)..(102)

&lt;223&gt; Complementary Determining Region

&lt;400&gt; 3

Asp Ile Gln Leu Thr Gln Ser Pro Leu Thr Leu Ser Val Thr Ile Gly

1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser

20 25 30

Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser

35 40 45

Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro

50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Asn Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly

85 90 95

Thr His Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Lys

100 105 110

```

<400> 4
Ile Pro Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
  1                      5                      10                      15

Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr
  20                      25                      30

Ser Tyr Trp Ile Asn Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu
  35                      40                      45

Trp Ile Gly Asn Ile Ser Pro Ala Asp Ser Ser Thr Asn Tyr Asn Gln
  50                      55                      60

Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr
  65                      70                      75                      80

Ala Tyr Met Gln Leu Ser Arg Pro Thr Phe Glu Asp Ser Ala Val Tyr
  85                      90                      95

Tyr Cys Ala Arg Glu Glu Val Arg Arg Arg Arg Asp Met Asp Phe Trp
  100                      105                      110

Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro
  115                      120                      125

Cys

```

<210> 5  
 <211> 122  
 <212> PRT  
 <213> Mus sp.

<220>  
 <221> BINDING  
 <222> (27)..(42)  
 <223> Complementary Determining Region

<220>  
 <221> BINDING  
 <222> (58)..(64)  
 <223> Complementary Determining Region

<220>  
 <221> BINDING  
 <222> (97)..(105)  
 <223> Complementary Determining Region

<400> 5  
 Arg Lys Leu Asp Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val  
 1 5 10 15  
 Thr Ser Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Arg Gln Ser Leu  
 20 25 30  
 Leu Tyr Lys Asn Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro  
 35 40 45  
 Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Met Ser Ile Arg Ala Ser  
 50 55 60  
 Gly Val Ser Asp Arg Phe Ser Gly Asn Gly Ser Gly Thr Asp Phe Thr  
 65 70 75 80  
 Leu Glu Ile Ser Arg Val Arg Ala Glu Asp Val Gly Val Tyr Tyr Cys  
 85 90 95  
 Gln Gln Leu Val Glu Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu  
 100 105 110  
 Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr  
 115 120

&lt;210&gt; 6

&lt;211&gt; 130

&lt;212&gt; PRT

&lt;213&gt; Mus sp.

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (26)..(35)

&lt;223&gt; Complementary Determining Region

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (50)..(66)

&lt;223&gt; Complementary Determining Region

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (99)..(113)

&lt;223&gt; Complementary Determining Region

&lt;400&gt; 6

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

1 5 10 15

Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr

20 25 30

Thr Ile Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile

35 40 45

Gly Leu Ile Asn Pro Tyr Asn Gly Gly Thr Cys Tyr Asn Pro Lys Phe

50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Arg Val Trp Leu Arg Arg Asp Gly Phe Tyr Tyr Ala Met Asp

100 105 110

Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr

115 120 125

Pro Pro

130

&lt;210&gt; 7

&lt;211&gt; 114

&lt;212&gt; PRT

&lt;213&gt; Mus sp.

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (13)..(27)

&lt;223&gt; Complementary Determining Region

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (43)..(49)

&lt;223&gt; Complementary Determining Region

&lt;220&gt;

&lt;221&gt; BINDING

&lt;222&gt; (82)..(90)

&lt;223&gt; Complementary Determining Region

&lt;400&gt; 7

Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Gln Ala Ser Glu  
 1 5 10 15

Ser Val Ser Phe Ala Gly Thr Ser Leu Met His Trp Tyr Gln Gln Lys  
 20 25 30

Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Lys Leu Glu  
 35 40 45

Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Glu Ser Asp Phe  
 50 55 60

Thr Leu Thr Ile Asp Pro Val Glu Glu Asp Asp Ala Ala Met Tyr Tyr  
 65 70 75 80

Cys Met Gln Ser Met Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys  
 85 90 95

Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro  
 100 105 110

Pro Ser

&lt;210&gt; 8

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

tcgagaggca tgtctaggca tgtctc

26

&lt;210&gt; 9

&lt;211&gt; 1307

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (126)..(1304)

&lt;400&gt; 9

accgtccagg gaggcaggtag ctgctgggct ccggggacac ttgctgttcg ggctgggagc 60

gtgctttcca cgacgggtgac acgcttcctt ggattggcag ccagactgcc ttccgggtca 120

ctgcc atg gag gag ccg cag tca gat cct agc gtc gag ccc cct ctg agt 170

Met Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser

1

5

10

15

cag gaa aca ttt tca gac cta tgg aaa cta ctt cct gaa aac aac gtt 218

Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val

20

25

30

ctg tcc ccc ttg ccg tcc caa gca atg gat gat ttg atg ctg tcc ccg 266

Leu Ser Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro

35

40

45

gac gat att gaa caa tgg ttc act gaa gac cca ggt cca gat gaa gct 314

Asp Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala

50

55

60

ccc aga atg cca gag gct gct ccc cgc gtg gcc cct gca cca gcg act 362

Pro Arg Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Thr

65

70

75

cct aca ccg gcg gcc cct gca cca gcc ccc tcc tgg ccc ctg tca tct 410

Pro Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser

80

85

90

95

tct gtc cct tcc cag aaa acc tac cag ggc agc tac ggt ttc cgt ctg 458

Ser Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu

100	105	110	
ggc ttc ttg cat tct ggg aca gcc aag tct gtg act tgc acg tac tcc			506
Gly Phe Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser			
115	120	125	
cct gcc ctg aac aag atg ttt tgc caa ctg gcc aag acc tgc cct gtg			554
Pro Ala Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val			
130	135	140	
cag ctg tgg gtt gat tcc aca ccc ccg ccc ggc acc cgc gtc cgc gcc			602
Gln Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala			
145	150	155	
atg gcc atc tac aag cag tca cag cac atg acg gag gtt gtg agg cgc			650
Met Ala Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg			
160	165	170	175
tgc ccc cac cat gag cgc tgc tca gat agc gat ggt ctg gcc cct cct			698
Cys Pro His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro			
180	185	190	
cag cat ctt atc cga gtg gaa gga aat ttg cgt gtg gag tat ttg gat			746
Gln His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp			
195	200	205	
gac aga aac act ttt cga cat agt gtg gtg gtg ccc tat gag ccg cct			794
Asp Arg Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro			
210	215	220	
gag gtt ggc tct gac tgt acc acc atc cac tac aac tac atg tgt aac			842
Glu Val Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn			
225	230	235	
agt tcc tgc atg ggc ggc atg aac cgg agg ccc atc ctc acc atc atc			890
Ser Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile			
240	245	250	255
aca ctg gaa gac tcc agt ggt aat cta ctg gga cgg aac agc ttt gag			938
Thr Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu			
260	265	270	
gtg cgt gtt tgt gcc tgt cct ggg aga gac cgg cgc aca gag gaa gag			986
Val Arg Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu			
275	280	285	
aat ctc cgc aag aaa ggg gag cct cac cac gag ctg ccc cca ggg agc			1034
Asn Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser			



290                                      295                                      300  
 act aag cga gca ctg ccc aac aac acc agc tcc tct ccc cag cca aag    1082  
 Thr Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys  
 305                                      310                                      315  
 aag aaa cca ctg gat gga gaa tat ttc acc ctt cag atc cgt ggg cgt    1130  
 Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg  
 320                                      325                                      330                                      335  
 gag cgc ttc gag atg ttc cga gag ctg aat gag gcc ttg gaa ctc aag    1178  
 Glu Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys  
 340                                      345                                      350  
 gat gcc cag gct ggg aag gag cca ggg ggg agc agg gct cac tcc agc    1226  
 Asp Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser  
 355                                      360                                      365  
 cac ctg aag tcc aaa aag ggt cag tct acc tcc cgc cat aaa aaa ctc    1274  
 His Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu  
 370                                      375                                      380  
 atg ttc aag aca gaa ggg cct gac tca gac tga                                      1307  
 Met Phe Lys Thr Glu Gly Pro Asp Ser Asp  
 385                                      390  
  
 <210> 10  
 <211> 393  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 10  
 Met Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln  
 1                                      5                                      10                                      15  
 Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu  
 20                                      25                                      30  
 Ser Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp  
 35                                      40                                      45  
 Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro  
 50                                      55                                      60  
 Arg Met Pro Glu Ala Ala Pro Arg Val Ala Pro Ala Pro Ala Thr Pro  
 65                                      70                                      75                                      80

Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser  
 85 90 95

Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly  
 100 105 110

Phe Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro  
 115 120 125

Ala Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln  
 130 135 140

Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met  
 145 150 155 160

Ala Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys  
 165 170 175

Pro His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln  
 180 185 190

His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp  
 195 200 205

Arg Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu  
 210 215 220

Val Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser  
 225 230 235 240

Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr  
 245 250 255

Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val  
 260 265 270

Arg Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn  
 275 280 285

Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr  
 290 295 300

Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys  
 305 310 315 320

Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu  
 325 330 335

Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp  
340 345 350


Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His  
355 360 365

Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met  
370 375 380

Phe Lys Thr Glu Gly Pro Asp Ser Asp  
385 390

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24443

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/141.1, 143.1, 185.1; 435/7.1, 372; 436/507, 514; 514/12, 13, 44; Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
Y	DONG, X. et al. Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and sv40 large T antigen. J. Exp. Med. April 1994, Vol. 179, pages 1243-1252, see entire document.	1-4, 7-30, 32-70												
Y	KREMER, J.M. Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arth. Rheum. May 1997, Vol. 40, No. 5, pages 980-985, see entire document.	1-4, 7-30, 32-70												
Y	US 5,472,693 A (GOURLIE et al) 05 June 1995, see sequence 4.	1-4, 7-30, 32-70												
Y	EP 0 438 312 A2 (MERCK & CO. INC.) 24 July 1991, see entire document.	1-4, 7-30, 32-70												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
*O* document referring to an oral disclosure, use, exhibition or other means														
*P* document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 30 DECEMBER 1999		Date of mailing of the international search report 02 FEB 2000												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  MARY BETH TUNG Telephone No. (703) 308-0196												

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24443

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 806 478 A2 (HEALTH RESEARCH, INC.) 12 November 1997, see entire document.	1-4, 7-30, 32-70
Y	WO 91/07493 A1 (XOMA CORPORATION) 30 May 1991, see entire document.	1-4, 7-30, 32-70
Y	WO 96/39518 A1 (BIONEBRASKA, INC.) 12 December 1996, see entire document.	1-4, 7-30, 32-70
Y	WO 92/22653 A1 (GENENTECH) 23 December 1992, see entire document.	1-4, 7-30, 32-70
Y	WO 97/04092 A1 (RHONE-POULENC RORER) 06 February 1997, see entire document.	1-4, 7-30, 32-70
Y	WO 94/19466 A2 (THE DOW CHEMICAL COMPANY) 01 September 1994, see entire document.	1-4, 7-30, 32-70

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24443

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 5, 6, 31  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/24443

### A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 31/70, 38/00, 39/00, 39/395; C12N 5/08; G01N 33/53, 33/564, 33/558

### A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/141.1, 143.1, 185.1; 435/7.1, 372; 436/507, 514; 514/12, 13, 44

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

MEDLINE, CANCERLIT, BIOSIS, EMBASE, SCISEARCH, WEST: all databases COMPUGEN (sequences)

T cell receptor, TCR, systemic lupus, SLE, ELISA, enzyme linked, anti-DNA p53 CDR, complementarity determining region, PAB-21